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“For small creatures such as we the vastness is bearable only through love.” 
 
Carl Sagan 
American astronomer (1934-1996)
  
ABSTRACT 
Background: Alzheimer disease (AD) is a neurodegenerative disorder, characterized by the 
accumulation of b-amyloid (Ab) plaques and tangles consisting of hyperphosphorylated tau-
protein in the brain. It accounts for 60-70% of dementia cases, making it the most common 
cause of dementia. In rare cases the disease is inherited in autosomal dominant early onset form 
caused by mutations in APP, PSEN1 or PSEN2. These familial forms of AD (FAD) allow for 
studies of the long preclinical stage of the disease and may thereby address unanswered 
questions about the natural history of AD which can be used to develop optimal tools for early 
diagnosis and for monitoring treatment response, as well as finding new possible treatment 
targets. To this end we conducted a prospective study, involving repeated clinical evaluations 
and collection of biomarkers from asymptomatic carriers of mutations leading to FAD with 
non-carriers (NC) from the same families as controls. The asymptomatic mutation carriers 
(MC) are good representatives of the preclinical stage of AD as they will develop symptoms 
of the disease in the future at an age which can be estimated based on the age at symptom onset 
in their family members who have already become symptomatic.  
Aims: To map biomarker changes in preclinical AD, as well as their temporal trajectories and 
sequence, through repeated collection and analysis of biomarkers in asymptomatic FAD MC 
and NC. 
Results: There were significant differences in the levels of the cerebrospinal fluid (CSF) 
biomarkers Ab42, total-tau protein (t-tau) and phosphorylated tau-protein (p-tau), as well as in 
the Ab42/p-tau ratio when comparing MC to NC, more than 7 years before the expected onset 
of symptoms in the MC. Ab42 and the Ab42/p-tau ratio were lower in MC than NC, while t-
tau and p-tau were higher in MC than NC. There was a trend of Ab42 and the Ab42/p-tau ratio 
decreasing as the onset of symptoms approached in MC, while t-tau and p-tau showed a trend 
of increasing with approaching symptom onset. On structural magnetic resonance imaging 
(MRI) of the brain, the MC had reduced volume of the left precuneus, left superior temporal 
gyrus and left fusiform gyrus, 9 years before the expected symptom onset. However, there was 
no observable decline in grey matter thickness or volume as the onset of symptoms approached, 
making the temporality of these changes difficult to assess. In the same group of subjects there 
was no significant difference on neuropsychological assessments between MC and NC, but a 
trend of poorer results was observed in the MC regarding immediate memory, episodic memory 
and attention/executive function. The CSF biomarkers YKL-40, reflecting glial activation, and 
neurogranin, a synaptic marker, were compared between asymptomatic MC and NC and found 
not to differ between the groups. A longitudinal study of changes in YKL-40 and neurogranin 
with approaching symptom onset was also conducted, revealing an increase in YKL-40 in both 
MC and NC as the age of symptom onset drew nearer, with a steeper increase in MC than NC. 
No such correlation to years to symptom onset was found for neurogranin. The APP processing 
products sAPPa, sAPPb, Ab42, Ab40 and Ab38 were compared both between the MC group 
as a whole and the NC and between subgroups of MC carrying specific mutations and the NC. 
The whole MC group had lower levels of Ab42, Ab40 and Ab38, as well as a lower 
Ab42/Ab40 ratio than NC. No significant correlation was observed between any of the 
aforementioned APP processing products and years to symptom onset in MC. When comparing 
different MC subgroups to each other, the whole MC group and the NC group, some mutation 
specific differences in the levels of the APP processing products and their temporality emerged. 
During the biomarker studies presented above the presence of a statistical outlier came to our 
attention, an MC carrying the PSEN1 H163Y mutation who had passed the age at symptom 
onset in his family but displayed no cognitive decline and no abnormalities in CSF biomarkers. 
This individual had been followed-up within the FAD study for 22 years and had opted for a 
presymptomatic genetic test, making his mutation status known to him and to the researchers 
involved in the study. His clinical case was characterized in paper III, with his brother serving 
as a control. The brother was only one year older than the outlier but had already passed away 
from AD at the end of the follow-up time, having displayed typical signs and symptoms of the 
disease in the preceding years. 
Conclusions: The study revealed early preclinical changes in CSF biomarkers, reflecting Ab 
aggregation, glial activation, tau phosphorylation and neurodegeneration, as well as loss of 
volume in specific areas in the left hemisphere of the brain on structural MRI in asymptomatic 
carriers of FAD mutations. When assessing the temporality of specific biomarkers in the CSF, 
Ab42 and the Ab42/p-tau ratio seemed to decrease with approaching symptom onset, while t-
tau and p-tau increased as symptom onset drew nearer. These results are based on cross-
sectional data, but only longitudinal studies can properly assess temporal changes, as we did 
for CSF neurogranin and YKL-40 (with YKL-40 increasing at a faster rate in MC than in NC). 
However, the overall results give an important indication of the true nature of these preclinical 
temporal changes. We also observed mutation specific differences in APP processing products 
in the CSF and characterized a case of reduced penetrance of the PSEN1 H163Y mutation. In 
conclusion, the study sheds light on preclinical biomarker changes in FAD and the possible 
sequence of these changes. It also emphasizes the differences in phenotype between specific 
FAD mutations and the presence of reduced penetrance which affects the estimation of 
symptom onset in these families and has an impact on genetic counseling and possibly on the 
design of clinical trials in this population. 
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1 INTRODUCTION 
1.1 ALZHEIMER DISEASE – AN OVERVIEW 
1.1.1 A brief history 
Alzheimer disease (AD) is a neurodegenerative disorder and the most common cause of 
dementia, accounting for 60-70% of dementia cases (1). The first clinical description of AD 
was made by Alois Alzheimer, a German psychiatrist and neuropathologist, working with Emil 
Kraepelin in Munich at the turn of the 20th century (2). In 1901 Alzheimer encountered a 51-
year old patient, Auguste Deter, suffering from pre-senile dementia with progressive memory 
loss, confusion and paranoid delusions. He followed Mrs. Deter’s clinical course until her death 
5 years later, registering widespread cognitive decline with increasing apathy and aphasia. 
After Mrs. Deter’s death, Alzheimer received her brain for histopathological examination and 
described the “plaques and tangles” that are now known to be the hallmarks of AD (3). In 1997, 
the tissue sections from Mrs. Deter were located at the Royal Psychiatric Clinic in Munich and 
re-examined. The tissue sections from the cerebral cortex, originally prepared according to the 
Bielschowsky method, revealed an abundance of neurofibrillary tangles and amyloid plaques 
in the upper cortical layers, exactly as previously described by Alzheimer (4).  
1.1.2 Neuropathology 
1.1.2.1 Amyloid plaques and neurofibrillary tangles 
For decades, AD has been neuropathologically characterized by neurodegeneration with a loss 
of neurons and synapses leading to progressive brain atrophy. Microscopically, it is defined by 
the presence of amyloid plaques and neurofibrillary tangles (NFTs) in the brain tissue (5, 6). 
Amyloid plaques are primarily made of extracellular aggregates of Ab42, an amyloid b peptide 
composed of 42 amino acids, and fall into two categories, diffuse plaques and dense-
core/neuritic plaques (7-9). Neuritic plaques stain positively with Congo-red or Thioflavin-S 
and are associated with dystrophic neurites, glial activation and loss of synapses and neurons. 
They are implicated in the pathogenesis of AD, while diffuse plaques are commonly believed 
to be the product of normal ageing (10). NFTs are made of hyperphosphorylated tau-protein, a 
protein which under physiological circumstances stabilizes microtubules within the axons of 
nerve cells. Tau hyperphosphorylation leads to the formation of intracellular straight and paired 
helical tau filaments (NFTs), which interfere with the structure and function of the affected 
neurons (11-14). Apart from neuritic plaques and NFTs the majority of AD cases involve 
multiple other pathological changes such as the deposition of TDP-43 (an RNA binding protein 
also associated with amyotrophic lateral sclerosis and frontotemporal lobar degeneration) (15) 
and a synuclein (a presynaptic protein also associated with Parkinson disease) (16). 
1.1.2.2 Spatiotemporal distribution of Alzheimer pathology based on post mortem studies 
Cerebral amyloidosis is an early event in AD and is now believed to arise years or decades 
before the onset of clinical symptoms of the disease (17-19). Typically, the earliest amyloid 
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plaques detected at autopsy are localized in the association neocortex, more specifically in the 
basal areas of the frontal, temporal and occipital lobes. The plaque pathology is then detected 
in other neocortical areas, apart from the primary sensory, motor and visual areas which are 
usually spared until the advanced stages of the disease. With disease progression, plaques also 
accumulate in the allocortex, including the hippocampal and entorhinal cortices (20-22). The 
correlation between clinical symptoms and the accumulation and distribution of amyloid 
plaques is not strong (23-26). NFTs have a much closer concordance with symptoms of AD as 
they first appear in the transentorhinal region and then the CA1 area of the hippocampus, 
followed by other limbic structures, the association cortex and finally the rest of the neocortex. 
Braak and Braak proposed a staging of NFT pathology, with stage I-II involving the 
transentorhinal region, stage III-IV other limbic areas and stage V-VI the neocortex (20). Loss 
of synapses and neurons matches the distribution of NFTs, both in space and time, and has a 
strong correlation to clinical symptoms. The best correlate of cognitive decline is synaptic 
density with synaptic loss preceding the death of neurons (24, 26-28).  
1.1.2.3 Neuropathological diagnostic criteria for Alzheimer disease 
In 1991, the Consortium to Establish a Registry for Alzheimer Disease (CERAD), suggested 
diagnostic criteria for AD based on the burden of neuritic amyloid plaques. The CERAD 
criteria involve scoring the density of neuritic plaques in the most severely affected region of 
the frontal, temporal or parietal neocortex, adjusted for the age of the subject. After 
incorporating clinical information on the absence or presence of dementia, subjects can be 
divided into three categories; possible Alzheimer disease, probable Alzheimer disease or 
definite Alzheimer disease (29, 30). These criteria proved to have high sensitivity but low 
specificity, while the opposite was true of the Braak and Braak staging described above (31).  
The National Institute of Aging and the Reagan Institute (NIA-RI) combined the CERAD and 
Braak and Braak criteria into consensus criteria in 1997 (32), excluding age as a factor in the 
neuropathological diagnosis (see table 1).  
Neuropathological assessment of the likelihood that Alzheimer disease accounts for a 
dementia should be judged as follows: 
1. High likelihood CERAD definite, Braak and Braak V/VI 
2. Intermediate likelihood CERAD probable, Braak and Braak III/IV 
3. Low likelihood CERAD possible, Braak and Braak I/II 
Table 1. The NIA-RI criteria for the neuropathological diagnosis of AD (32). 
A requirement of the NIA-RI criteria is that the subject has a dementia diagnosis. As mentioned 
earlier, it has become apparent in recent years that AD has a long preclinical phase and the 
neuropathology of the disease precedes the symptoms by years or decades (18). Therefore, new 
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neuropathological criteria were proposed by the National Institute of Aging-Alzheimer´s 
Association (NIA-AA) workgroups in 2012, partly to incorporate this preclinical phase into the 
neuropathological diagnosis (19). Here, the requirement for the presence of dementia was 
abandoned and an increased emphasis was put on recording the presence of brain lesions 
related to conditions commonly comorbid to AD. Neuropathological results according to the 
NIA-AA criteria are reported in an “ABC” system, where A represents amyloidosis, B 
represents Braak stage and C represents the CERAD plaque score (see table 2)  (19).  
A. Ab plaque score (modified from Thal et al. (22)): 
A0: no Ab or amyloid plaques 
A1: Thal phase 1 or 2 
A2: Thal phase 3 
A3: Thal phase 4 or 5 
B. NFT stage: 
B0: no NFTs 
B1: Braak stage I or II 
B2: Braak stage III or IV 
B3: Braak stage V or VI 
C. Neuritic plaque score: 
C0: no neuritic plaques 
C1: CERAD score sparse 
C2: CERAD score moderate 
C3: CERAD score frequent 
Table 2. The NIA-AA criteria for the neuropathological diagnosis of AD, Hyman et al., 2012 (19) 
After staging Alzheimer pathology according to the “ABC” system above, each case receives 
a score of AD pathologic change according to severity; “Not”, “Low”, “Intermediate” or 
“High”. The presence of “Intermediate” or “High” AD pathology is considered sufficient to 
explain symptoms of dementia. As mentioned earlier, the NIA-AA criteria also require that 
signs of comorbidities such as Lewy body disease, vascular brain injury and hippocampal 
sclerosis are noted.  
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1.1.3 Stages of Alzheimer disease 
1.1.3.1 Preclinical Alzheimer disease 
AD is believed to have a long preclinical phase, during which the affected individual has no or 
very subtle decline in cognition but manifests AD biomarker positivity (17, 18, 33, 34). The 
characterization of the preclinical stage of AD first became possible following the emergence 
of in vivo biomarkers, such as neuroimaging with magnetic resonance imaging (MRI) and 
positron emission tomography (PET) and biomarkers in the cerebrospinal fluid (CSF), 
reflecting cerebral amyloidosis, tau phosphorylation and neurodegeneration. The time span of 
preclinical AD has of yet not been fully elucidated as it seems to manifest some individual 
variability and could be affected by factors such as cognitive reserve, genetic profile and 
lifestyle (34). However, mounting evidence suggests that the preclinical stage is generally long, 
stretching over years or even decades (35).  
In 2010, Jack et al. proposed a hypothetical model of biomarker change in AD, spanning the 
whole continuum of the disease, from the preclinical stage through to the stages of mild 
cognitive impairment (MCI) and dementia (17). The model was amended in 2013 postulating 
that biomarkers reflecting amyloid b deposition in the brain such as CSF Ab42 and amyloid 
PET become abnormal first, followed by biomarkers reflecting tau pathology, such as CSF 
total tau protein (t-tau) and phosphorylated tau (p-tau). Finally, close to the onset of clinical 
symptoms, changes can be seen on structural MRI and on [18F]fluorodeoxyglucose (FDG)-
PET, signaling the onset of cerebral atrophy and neuronal death. Substantial evidence already 
supports this hypothetical model (33, 36-45), but prospective longitudinal studies, spanning 
decades, will be needed to fully understand the trajectories of different biomarkers in 
preclinical AD.  
1.1.3.2 Mild cognitive impairment 
Individuals with underlying AD pathology eventually progress from preclinical AD to mild 
cognitive impairment (MCI) (46), as they move along the continuum of AD. To fulfill the 
diagnostic criteria of MCI the patient, an informant, or a clinician responsible for the care of 
the patient needs to have observed a decline from the patient’s previous level of performance 
on objective cognitive tasks. The impairment must be greater than expected based on the age 
and education level of the patient. It can be in one or more cognitive domains, e.g. memory, 
executive function, visuospatial ability, attention and/or language. Impairment in episodic 
memory, often referred to as amnestic MCI (47), is the form of MCI that most commonly 
progresses to AD dementia with an annual conversion rate of around 10% (48). This typical 
AD amnestic MCI phenotype, along with a positive AD biomarker(s), is often referred to as 
prodromal AD (49). A series of cognitive assessments showing a steeper cognitive decline over 
time than observed in age and education matched peers is feasible, but not necessary, as a basis 
for a diagnosis of MCI. An individual presenting with subjective cognitive symptoms that 
cannot be verified by objective cognitive testing is categorized as having subjective cognitive 
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impairment (SCI), a condition that has been shown to be related to increased risk of harboring 
underlying AD pathology (50). 
In order to receive an MCI diagnosis, the patient needs to fulfill the MCI criteria above but 
have preserved functional abilities in daily life. That is, the patient cannot be demented. In 
determining that MCI is due to underlying AD pathology it is important to exclude other 
conditions that might be responsible for the cognitive impairment, such as vascular, traumatic, 
psychiatric and metabolic causes (47, 51).  
1.1.3.3 Dementia 
In AD, the transition from MCI to dementia is usually gradual, heralded by a loss of functional 
abilities in daily life. Both MCI and dementia are clinically defined entities open to subjective 
interpretation by the patient, knowledgeable informants and clinicians. Diagnostic guidelines 
for the whole of the AD continuum, the preclinical stage, MCI and dementia stages were 
proposed by the NIA-AA in 2011 and have already been detailed for the first two stages in the 
sections above.  
According to these current criteria for dementia diagnosis the first step is to determine if 
dementia is present and thereafter if it is probably or possibly due to AD. The NIA-AA criteria 
for all-cause and AD dementia are detailed in table 3 (52). 
The NIA-AA criteria replace the National Institute of Neurological and Communicative 
Disorders and Stroke (NINCDS) and the Alzheimer´s Disease and Related Disorders 
Association (ADRDA) criteria from 1984 (53). A patient fulfilling the NINCDS-ADRDA 
criteria for probable AD would also meet the new NIA-AA criteria, while a patient fulfilling 
the NINCDS-ADRDA criteria for possible AD would have to be reevaluated.  
The NIA-AA criteria include new categories not included in previous diagnostic criteria, 
namely probable or possible AD dementia with evidence of the AD pathophysiological 
process. Here, biomarkers of AD pathophysiology reflecting amyloid b deposition and 
neurodegeneration have been incorporated into the criteria. Due to several issues concerning 
the use of AD biomarkers, including lack of standardization and of quantitative analytical 
techniques, the use of biomarkers is still optional in the clinical setting but can be of value for 
research purposes.  
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Criteria for all-cause dementia: 
Dementia is diagnosed when there are cognitive or behavioral symptoms that: 
1. Interfere with the ability to function at work or at usual daily activities. 
2. Represent a decline from previous functional level. 
3. Are not explained by delirium or a major psychiatric disorder. 
4. Cognitive impairment is diagnosed through a combination of (1) history taking from the patient and a 
knowledgeable informant and (2) an objective cognitive assessment. 
5. The cognitive or behavioral impairment involves a minimum of two of the following domains: 
a. Impaired ability to acquire and remember new information. 
b. Impaired reasoning and handling of complex tasks. 
c. Impaired visuospatial abilities. 
d. Impaired language functions. 
e. Changes in personality, behavior or comportment 
Probable AD dementia: 
Meets criteria for all-cause dementia and has the following characteristics: 
A. Insidious onset. 
B. Clear-cut history of worsening. 
C. The initial and most prominent cognitive deficits are evident in one of these two categories; (a) 
Amnestic presentation or (b) Non-amnestic presentation (this includes language presentation, 
visuospatial presentation and executive presentation). 
D. The diagnosis of probable AD dementia should not be made when there is evidence of substantial 
concomitant cerebrovascular disease, core features of dementia with Lewy bodies, prominent features 
of behavioral variant frontotemporal dementia, prominent features of semantic variant primary 
progressive aphasia or non-fluent variant primary progressive aphasia or evidence for another active  
neurological disease or a non-neurological medical comorbidity or use of medication that could have 
a substantial effect on cognition. 
 
Possible AD dementia: 
A diagnosis of possible AD dementia should be made in the two following circumstances:  
A. The course is atypical, e.g. the onset is sudden or the documentation of progressive cognitive decline 
is insufficient. 
B. The presentation is etiologically mixed, meeting all core clinical criteria for AD dementia, but has 
evidence of concomitant cerebrovascular disease, features of dementia with Lewy bodies or evidence 
of another neurological disease or a non-neurological medical comorbidity or medication use that 
could have a substantial effect on cognition. 
 
Table 3. NIA-AA diagnostic guidelines for dementia due to AD, based on McKhann et al. 2011 (52). 
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1.1.3.4 Stages of dementia 
For research and therapeutic purposes, it is important to define stages of dementia due to AD, 
as it progresses over a period of several years with continuing cognitive deterioration of the 
affected individual. The Washington University Clinical Dementia Rating Scale (CDR) (54) 
was developed to assess the severity of dementing illnesses. It requires information both from 
the patient and from a knowledgeable informant on the level of impairment in six domains; 
memory, orientation, judgment and problem solving, community affairs, home and hobbies 
and personal care. The impairment in each category is rated as absent, questionable, mild, 
moderate or severe, after which an algorithm is used to generate an overall category of severity. 
This final overall CDR score rates the patient´s symptoms as no dementia (CDR = 0), 
questionable dementia (CDR = 0.5), mild dementia (CDR = 1), moderate dementia (CDR = 2) 
or severe dementia (CDR = 3) (55).  
Typical symptoms of mild AD dementia include impairment in episodic memory and executive 
function and changes in personality. When the patient progresses to moderate dementia these 
symptoms become more pronounced with added confusion, increased dependence on others 
for assistance with activities of daily living and behavioral and psychiatric symptoms often 
develop at this stage. In the final, severe, stage of AD dementia the patient becomes dependent 
on others for all activities of daily living, including personal care, and loses the ability to 
communicate. Towards the end of this stage the patient´s motoric functions deteriorate leaving 
the patient unable to walk, swallow or control bladder and bowel functions (56). 
The CDR is a valid and reliable instrument for scoring the severity of dementia but it can be 
impractical as it is time consuming to administer and requires information from more than one 
individual. Therefore, the Mini-Mental State Examination (MMSE) was mapped onto the CDR 
categories in the hope that the MMSE could serve as a surrogate for the CDR (57). The MMSE 
is a short cognitive screening tool that can be administered in 10 – 15 minutes and only requires 
the patient to take part (58). The results of an MMSE are on the scale from 0 to 30, where 0 is 
the lowest outcome (severe impairment) and 30 the highest (no impairment). According to the 
results from the mapping of the CDR onto the MMSE, the MMSE is a good surrogate for the 
CDR with an MMSE score of 26-29 corresponding to a CDR score of 0.5 (questionable), 21 – 
25 corresponding to CDR 1 (mild), 11 – 20 corresponding to CDR 2 (moderate) and 0 – 10 
corresponding to CDR 3 (severe). 
 
1.1.4 Epidemiology and economic impact 
It is estimated that 46.8 million people worldwide were living with dementia in 2015 and that 
60 – 70% of these patients had AD as an underlying cause (1). By 2050 this number will have 
risen to 131.5 million according to the World Alzheimer Report, due to the ageing of the global 
population (59). This increase has already become apparent in recent years with the number of 
people who are disabled or die from dementing illnesses having more than doubled in the 
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period from 1990 to 2015 (60). In 2015 the total global societal cost of dementia, including 
direct medical costs, direct social costs and indirect social costs, was estimated to be US$ 818 
billion, equal to 1.1% of global gross domestic product (1). These costs are predicted to rise 
substantially in the future, in the context of increasing prevalence of dementing illnesses. 
The global prevalence of all-cause dementia in people over the age of 60 is generally reported 
to be in the range of 5 – 8% (1). The estimated annual period prevalence of AD in this age 
group in a community setting is significantly higher in North America (103.6 per 1000 
individuals) than in Asia (11.7 per 1000 individuals) and Europe (31.3 per 1000 individuals). 
Trends of regional differences have also been observed in other settings but have not been 
statistically significant. Explanations for these differences between regions could include 
differences in diagnostic criteria, variation in disease reporting, different thresholds for 
diagnosis, differences in age-distribution between populations, overall life expectancy and 
other competing risks (61). During the period from 1990 to 2015 a slight increase in the 
prevalence of dementia was observed in high-income North America, high-income Asia, the 
Caribbean and Southern sub-Saharan Africa with a modest decrease in prevalence being 
observed elsewhere (60).  
The age-standardized prevalence of dementia is 22% higher for women than for men. The 
reasons for this are not fully understood but the gender difference might be attributed, at least 
partly, to the fact that most epidemiological studies have defined their oldest age category as 
80 years and older. As women live longer they are overrepresented in this category, especially 
at the older end of its spectrum, and it would be feasible to break it up into smaller subcategories 
to see if these differences hold true in the oldest old (60, 61). 
When looking specifically at Sweden, The Swedish National Board on Health and Welfare 
reported that 158.000 people were living with dementia in Sweden in 2012. The total cost of 
dementia care in Sweden amounted to 63 billion Swedish crowns in 2012, or approximately 
7.4 billion US$ (62). 
 
1.1.5 Treatment 
Currently, only symptomatic treatment is available for dementia due to AD. It is not disease 
modifying as it does not slow down or halt the pathophysiological processes of the disease. 
Two categories of medication have been approved for symptomatic relief of AD dementia, 
acetylcholinesterase inhibitors (CheI) and N-Methyl-D-Aspartic (NMDA) receptor antagonists 
(63, 64).  
Donepezil is a CheI that binds reversibly to and inhibits acetylcholinesterase, an enzyme that 
degrades acetylcholine as it is released from the presynapse (65). As AD causes an early 
degeneration of cholinergic synapses (66, 67), there is a deficit of acetylcholine in AD that can 
be ameliorated in part through the administration of donepezil. Donepezil is approved for use 
in mild and moderate dementia due to AD in more than 90 countries around the world and even 
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for severe dementia in the United States, Canada, Japan and a few other countries. Most trials 
on the efficacy of donepezil show modest benefits on measures of cognition, activities of daily 
living and behavior, but not on overall quality of life (68). These trials were usually conducted 
over a period of 6 months or less, but there are a few studies that support the long-term efficacy 
of donepezil (69, 70).  
Two other CheI´s have been approved for use in mild to moderate AD, galantamine and 
rivastigmine. Galantamine is an acetylcholinesterase inhibitor and an allosteric potentiator of 
nicotinic and muscarinic acetylcholine receptors (71), while rivastigmine is a reversible 
inhibitor of both acetylcholinesterase and butyrylcholinesterase (72). Generally, placebo 
controlled trials have shown similar sustained but modest benefits of galantamine and 
rivastigmine as of donepezil (73-79). However, only a few studies have compared different 
CheI´s head-to-head. When comparing donepezil and galantamine, galantamine was found to 
have a slightly larger benefit regarding cognition and caregiver relief (80). Rivastigmine, which 
is the only CheI available as a skin patch, had less gastrointestinal side effects than the other 
CheI´s which are administered orally (81). Also, the rivastigmine skin patch performed slightly 
better on activities of daily living and global function than donepezil (82). To date, CheI´s are 
only approved for different stages of AD dementia, but not for MCI. According to a systematic 
review on all three types of CheI´s their use in patients with MCI was not associated with a 
delay in the onset of dementia (83). 
Memantine is a noncompetitive, low- to medium-affinity antagonist of cerebral NMDA 
glutamate receptors and the only drug approved for treatment of AD that is not a CheI. 
Neuronal excitotoxicity, due to prolonged influx of Ca2+ ions through NMDA receptors, is 
believed to be involved in the pathophysiology of AD. Memantine inhibits this influx of Ca2+, 
but as its binding is noncompetitive, the NMDA receptor can still serve its physiological 
purpose through activation by glutamate (84-86). In light of results from randomized clinical 
trials on memantine it has been approved for treatment of moderate to severe AD. In this 
setting, memantine treatment is effective in preventing and treating behavioral and psychiatric 
symptoms such as aggression, agitation, hallucinations and delusions (87, 88). A 28-week 
randomized controlled trial showed a modest improvement in independence, global well-being, 
daily function and attention in those taking memantine compared to a placebo group (89). 
Memantine has also been studied in combination with donepezil in patients with moderate to 
severe dementia due to AD. In a trial of 404 patients, lasting for 6 months, memantine 
augmented the positive effects of donepezil on cognition, activities of daily living, global 
outcome and behavior (90). 
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1.2 GENETICS OF ALZHEIMER DISEASE AND THE AMYLOID HYPOTHESIS 
Alzheimer disease is often categorized into early onset AD (EOAD), with the debut of clinical 
symptoms occurring at the age of 65 or younger, and late onset AD (LOAD), when the disease 
becomes symptomatic after the age of 65. EOAD, which represent 2-10% of AD cases, is 
considered to be a genetic disorder (91, 92). Autosomal dominant mutations in three genes, 
APP, PSEN1 and PSEN2 are known to cause early onset autosomal dominant AD (from here 
on referred to as familial AD or FAD) but these known mutations account for only 5-10% of 
EOAD cases (91). Genetic factors also have a large influence on the occurrence of LOAD, 
which has an estimated heritability of 60 – 80% (93). Currently, there are 40 known genes and 
susceptibility loci that have either a confirmed or suspected association with increased risk of 
LOAD, including the most well known risk gene APOE (91, 94). In 2013, Lambert et al. 
published the results of the largest multi-center international collaborative effort in AD genetics 
to date, The International Genomics of Alzheimer’s Project (IGAP), where 19 susceptibility 
loci, in addition to APOE, reached genome wide significance for AD (95). The study included 
74.046 individuals of European ancestry in which a two-stage meta-analysis of genome-wide 
association studies (GWAS) was performed. Of the 19 loci reported in this study, 11 were 
newly identified, illustrating the statistical power of this multi-center effort. The IGAP study 
from 2013 included 797 Swedish AD patients and 1506 controls, making the results relevant 
for the Swedish population. Since 2013, IGAP and other study groups have, as previously 
stated, yielded a total of 40 susceptibility loci for AD (94, 96, 97). 
1.2.1 Familial Alzheimer disease 
Familial Alzheimer disease (FAD) is an early onset form of AD where a known pathogenic 
mutation in one of three genes, APP, PSEN1 or PSEN2, is present. FAD is a very rare disease, 
estimated to account for <1% of AD cases (91). Mutations leading to FAD are considered to 
be close to 100% penetrant (98), with a predictable age at onset of symptoms, derived from the 
mean age at symptom onset of the affected members in each FAD family (99). However, there 
are a few FAD families that seem to be an exception to this rule, with wide ranges of symptom 
onset and suspected cases of reduced mutation penetrance (100-103). 
Numerous studies on mutation carriers from FAD families have contributed valuable 
information on the natural history and possible pathological mechanism of both FAD and the 
much more common sporadic form of AD (SAD). FAD mutation carriers are believed to be 
able to serve as models for SAD with the only difference between FAD and SAD being the 
heritability and generally young age at symptom onset in FAD. Several studies have addressed 
the possible phenotypic differences between FAD and SAD and found no significant 
differences in the duration of illness, rate of cognitive decline or occurrence of non-cognitive 
symptoms when comparing FAD and SAD cases (104, 105). No significant differences in 
cognitive phenotype were found when comparing the neuropsychiatric profiles of AD patients, 
with and without familial AD aggregation (106). In this case however, the study did not involve 
cases with known FAD mutations which could mean that the results are not generalizable to 
FAD. Finally, the neuropathology of FAD and SAD appears to be similar, with no observed 
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differences between severity scores or distribution of neuritic plaques and NFTs (107, 108). 
However, there are numerous known mutations causing FAD (see below) and a few of these 
have a distinct phenotype that differs from the typical phenotype of SAD (109), even though 
these differences disappear when pooling together individuals from many families carrying 
different FAD mutations. That such differences exist is important to keep in mind when using 
mutation carriers from a single FAD family as models for SAD. 
A great deal of what is known about the preclinical stage of AD comes from studies on 
cognitively asymptomatic individuals carrying FAD mutations (18). The fact that FAD 
mutations have a high degree of penetrance and a reliable age at symptom onset enables the 
mapping of the temporal trajectories of preclinical AD biomarker changes as the time point of 
symptom onset in each individual can be anticipated ahead of time. As FAD becomes 
symptomatic before the age of 65 in most cases, these subjects usually lack comorbidities such 
as cerebrovascular disease, which are common in older individuals with SAD. Therefore, FAD 
subjects allow for the study of AD in its purest form. 
1.2.1.1 APP processing 
Mutations leading to FAD all have an effect on the processing of the amyloid precursor protein 
(APP) or on the conformational structure of the b amyloid peptide. APP is a single-pass 
transmembrane protein with a large extracellular domain which includes the b amyloid 
sequence (110). Its cleavage can follow one of two pathways, an amyloidogenic pathway 
generating b amyloid (Ab) and a non-amyloidogenic pathway. In the amyloidogenic pathway, 
APP is first cleaved by a membrane-bound protease named b-secretase (BACE1) and then by 
another membrane-bound protease, g-secretase (see figure 1). Following cleavage by b-
secretase a soluble APPb (sAPPb) ectodomain is released, with a b C-terminal membrane 
bound intracellular fragment (bCTF) remaining. The bCTF is then cleaved by g-secretase, 
releasing an Ab peptide, as well as an APP intracellular domain (AICD). In the non-
amyloidogenic pathway, APP is cleaved by a-secretase, within the Ab sequence, precluding 
the formation of Ab. Following this cleavage, a soluble APPa (sAPPa) ectodomain is released 
which includes a part of the N-terminus of Ab, leaving an a C-terminal fragment (aCTF) 
behind in the cell membrane. This aCTF is then cleaved by g-secretase, releasing a 3 kDa 
peptide (p3) and an AICD. 
 
 20 
 
Figure 1. The amyloidogenic and non-amyloidogenic pathways of APP processing. Modified from 
Wang et al. 2012 (111). 
 
The APP processing pathways described above give a somewhat simplified view of APP 
cleavage, as the number of proteases that cleave APP is considerably larger. These proteases 
include the zinc metalloproteases ADAM17, ADAM9, ADAM10 and MDC-9, all cleaving 
APP at the a-secretase site, as well as the aspartyl protease b-site APP-cleaving enzyme 2 
(BACE2) which can cleave APP at the b-secretase site (112). BACE2 is closely related to the 
b-secretase mentioned above, BACE1, with BACE1 being the most abundant b-secretase in 
neurons. BACE1 usually cleaves APP at the b-secretase site, enabling the consequent release 
of Ab, but can also cleave APP within the Ab domain, albeit not at the same site as a-secretase 
(113). The recent discoveries of alternative APP fragments, e.g. N-terminally extended Ab, has 
hinted at the existence of even more proteases targeting APP (114). One of these secretases, h-
secretase, is a matrix metalloprotease which cleaves APP 92 amino acids upstream of the 
cleavage site of BACE1. This step of APP processing results in hCTFs which in turn are 
cleaved by a- or b-secretase yielding Ah-a and Ah-b peptides (115). These alternative APP 
processing products become more abundant following the administration of b-secretase 
inhibitors, but their physiological and possible pathological significance remains to be 
elucidated (115). The cleavage of the bCTF by g-secretase also yields different lengths of Ab 
species, discussed further in chapter 1.2.1.3. 
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1.2.1.2 APP mutations 
The APP gene was discovered in 1987 and localized to chromosome 21 (116-118). This 
discovery did not come entirely as a surprise due to the common occurrence of AD in people 
with trisomy 21, also known as Down syndrome  (119). People with Down syndrome develop 
dementia approximately 30 years ahead of the general population, with a mean symptom onset 
of 56 years (120, 121). The first APP mutations leading to FAD were discovered in the early 
nineties (122-125), strongly underpinning the central role of Ab in the pathogenesis of AD. 
The knowledge of the existence of APP mutations enabled the development of APP transgenic 
mouse models which have since then been central to research on AD molecular pathogenesis 
(126).  
Currently, 58 APP mutations have been identified, many of which are associated with FAD 
and a few which are related to cerebral amyloid angiopathy (CAA) (127). The known APP 
mutations are generally autosomal dominant, except for the E693 delta mutation (128) and the 
A673V mutation (129), which are autosomal recessive. APP mutations have been found near 
the cleavage sites of  g-secretase, a-secretase and b-secretase as well as at other locations along 
the Ab sequence (see figure 2). The majority of APP mutations with a known biological effect 
lead to an increase in the overall production of Ab and/or an increase in the Ab42/Ab40 ratio 
(127), but Ab40 is a shorter, less fibrillogenic and more common species of Ab than Ab42 
(130). The KM670/671NL (Swedish) (123) and A692G (Flemish) (131) mutations do not 
change the Ab42/Ab40 ratio, but increase overall Ab production. Most of the mutations located 
around the g-secretase cleaving site, such as V717I (London) (122), V717G (124) and V717F 
(Indiana) (125), do not affect the amount of total Ab but increase the Ab42/Ab40 ratio. The 
H677R (English) (132) and D678N (Tottori) (133) mutations increase Ab oligomerization and 
cytotoxicity, but do not affect the levels of Ab or the Ab42/Ab40 ratio. The same applies to 
the E693G (Arctic) (134, 135) and E693del (Osaka) (128) mutations which both enhance the 
propensity of Ab to oligomerize and form fibrils.  
One APP mutation stands out in having a protective effect against AD, as opposed to all the 
other known causal APP mutations. The A673T (Icelandic) mutation is located at the b-
secretase cleaving site and decreases the total amount of Ab by about 40% with the generated 
Ab being less prone to aggregation than wild type Ab (136, 137).  
More of the APP mutations with a known mechanism are illustrated in figure 2, however this 
is not a complete overview of all APP mutations with a known effect. 
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Figure 2. Locations of mutations in APP along the Ab peptide sequence. The Ab peptide sequence (in 
red) has been enlarged and its single amino acid code indicated in letters. The cleavage sites of the g-
secretase, a-secretase and b-secretase are illustrated with dotted lines. Modified from Bateman et al. 
2011 (138). 
 
1.2.1.3 Mutations in PSEN1 and PSEN2 
The most common mutations causing FAD are located in the PSEN1 gene on chromosome 14, 
with the first PSEN1 mutation being described in 1995 (139). PSEN2 mutations on 
chromosome 1, also first discovered in 1995 (140, 141), are the rarest types of FAD mutations 
(142, 143). To date, 241 PSEN1 mutations and 45 PSEN2 mutations have been reported (127). 
Presenilin is one of the four proteins that constitute the g-secretase, the others being nicastrin, 
anterior pharynx-defective 1 (APH-1) and presenilin enhancer 2 (PEN-2) (144). Presenilin, an 
aspartyl protease with nine transmembrane domains (145-148), is the catalytic subunit of g-
secretase (149). The PSEN1 and PSEN2 genes encode homologous presenilin proteins, 
presenilin-1 and presenilin-2, both being able to serve as the catalytic subunit of the g-secretase 
complex (145-147). The g-secretase cleaves APP several times, removing 3 to 4 C-terminal 
amino acids each time (see figure 3) (150, 151). The initial cleavage, the e-cleavage, occurs 
near the transmembrane/cytoplasmic interface of APP, either between Ab48 and Ab49 or 
between Ab49 and Ab50. The e-cleavage yields Ab48 and Ab49 peptides, depending on the 
starting point, which are then cleaved again, usually 2 – 3 times (152-154). The most common 
end product of this sequential APP cleavage is Ab40 (constituting 80 – 90% of the Ab peptides 
which are released), followed by Ab42 (5 – 10% of released Ab peptides) (130). Longer Ab 
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peptides such as Ab42 and Ab43 are more hydrophobic and neurotoxic than Ab40 and have a 
greater propensity to aggregate (155-157). Ab42 is the most abundant Ab peptide in neuritic 
plaques (155), with Ab40 being the most common Ab peptide to accumulate in blood vessels 
(157, 158). Ab43 is a relatively rare and highly neurotoxic peptide (159) which is more frequent 
in plaque cores than Ab40 both in the brains of patients with SAD and FAD (160). 
 
 
Figure 3. The sequential cleavage of APP by the g-secretase, releasing either an Ab40- or Ab42-peptide. 
Modified from Selkoe & Hardy 2016 (161). 
 
The g-secretase is not only responsible for APP processing but also the cleavage of several 
other substrates including another type-1 transmembrane protein, the cell surface receptor 
Notch (162). The Notch signaling pathway is important for the differentiation of a wide variety 
of cell types, both during development and in adulthood (163). The fact that g-secretase is not 
restricted to the APP processing pathway has proven to be a challenge in the development of 
AD treatment strategies based on g-secretase inhibition. 
PSEN1 mutations with a known biological effect have an influence on the g-secretase and often 
seem to cause a loss-of-function of presenilin. This leads to an early halt in the sequential 
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cleavage of APP, resulting in a relatively increased release of longer Ab peptides (161). Many 
known PSEN1 mutations, such as the M139V, H163Y, H163R and L286V mutations, cause 
an increase in the Ab42/ Ab40 ratio but not in overall Ab production, which is potentially due 
to this loss-of-function (139, 164, 165). Some PSEN1 mutations increase the Ab42/ Ab40 ratio 
and the absolute levels of Ab42 (164-167) and sometimes also the absolute levels of Ab40. 
Others increase the Ab42/ Ab40 ratio but decrease the absolute levels of either Ab40 or of both 
Ab42 and Ab40. Finally, the R278I mutation has been shown to specifically increase the 
amount of Ab43. This is not an exhaustive list of all PSEN1 mutations and their effects, but an 
increase in the relative or absolute amounts of longer Ab peptides seems to be common to the 
majority of them.  
Most of the known PSEN2 mutations increase both the Ab42/ Ab40 ratio and the absolute 
levels of Ab42 (140, 141, 168). However, at least one pathogenic PSEN2 mutation (V148I) 
neither affects the Ab42/ Ab40 ratio nor the levels of Ab42 (169). The age at symptom onset 
for PSEN2 mutations is 39 – 75 years, which is a wider range and later onset than in PSEN1 
and APP mutations (170). The reasons for this have not been fully elucidated but there are 
speculations that presenilin-1 might compensate for defects in the function of presenilin-2. This 
has been supported by a study on knockout mice, where PSEN2 knockouts were viable as 
opposed to mice with both PSEN1 and PSEN2 knocked out (171). 
1.2.1.4 Penetrance of FAD mutations 
The FAD mutations presented in the chapter above are generally considered to be close to 
100% penetrant, i.e. cause clinical symptoms of AD in all mutation carriers, and have a 
relatively invariant and predictable age at which the onset of clinical symptoms occurs (172). 
However, a few cases of suspected reduced penetrance of these mutations have been described 
in the literature. The median age at onset for the PSEN1 I143F mutation is 55 years but a carrier 
of this mutation was symptom free at the age of 68 (100). In another report the PSEN1 A79V 
mutation (with a mean onset age of 64 years) was not yet penetrant in a 76- year old mutation 
carrier (101). In both of these cases the symptom free mutation carriers had the APOE ε3/ε3 
genotype. In a family carrying the PSEN1 M139V mutation there were 34 years between the 
individual with the youngest onset (35 years of age) and the individual with the oldest onset 
(69 years of age), and they both had the same APOE genotype (ε3/ε4). Finally, three cases of 
AD due to the PSEN1 K239N mutation have been described, with a range of symptom onset 
from 42-71 years (based on clinical history). All of the three K239N mutation carriers had the 
APOE ε3/ε3 genotype (103). Reduced penetrance of the APP A713T mutation has also been 
reported (173), emphasizing that reduced penetrance of FAD mutations is not exclusive to 
PSEN1 mutations. These variations in onset and rare cases of reduced penetrance of FAD 
mutations are intriguing and suggest that genetic, epigenetic or environmental factors modify 
the disease process. 
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1.2.2 Genetic risk factors for late onset Alzheimer disease 
1.2.2.1 APOE 
APOE is an apoliprotein, or fat binding protein, produced by several cell types including 
astrocytes (174). It is the main carrier of cholesterol in the brain and forms chylomicrons and 
intermediate density lipoprotein particles along with triglycerides, phospholipids and 
cholesterol (175, 176). APOE has been shown to be involved in the trafficking of APP, in APP 
processing and in the clearance of Ab (177). The APOE gene on chromosome 19 has three 
alleles which code for APOE, e2, e3 and e4, resulting in six possible APOE genotypes (e2/e2, 
e2/e3, e2/e4, e3/e3, e3/e4 and e4/e4) (178). In 1993, the APOE e4 allele was recognized as a 
risk allele for LOAD, increasing the risk of developing AD 3– to 4-fold for APOE e4 
heterozygotes (179-181). Around 25% of the general population carry at least one e4 allele, 
94% at least one e3 allele and 15% at least one e2 allele, making the e2 allele the least common 
of the three (178). The e2 allele has been shown to reduce the likelihood of developing AD, 
while the e3 allele is considered to be neutral in this aspect (179). The mechanism by which 
the APOE e4 allele increases AD risk has been proposed to involve its failure to efficiently 
mediate the clearance of Ab (177). 
1.2.2.2 Other AD risk genes 
Several new loci associated with increased risk of developing AD have been discovered in 
recent years, but none as common and potent as APOE (161). ATP-binding cassette transporter 
7 (ABCA7) is a lipid transporter which, like APOE, is involved in cholesterol metabolism as 
well as in Ab homeostasis (182). Mutations in the ABCA7 gene, which cause a loss-of-function 
of this lipid transporter, increase the risk of developing AD around threefold (183, 184). Genes 
related to other mechanism besides cholesterol/sterol metabolism, including 
inflammation/innate immune responses and endosomal vesicle recycling, have also been linked 
to increased AD risk (161). Complement receptor 1 (CR1), CD33 and TREM2 are an example 
of the former (181, 185-187). All three encode proteins expressed by microglia that have been 
implicated in the phagocytosis of Ab deposits and are upregulated in response to increasing Ab 
plaque load. SORL1 is an example of the latter, encoding sortilin-related receptor 1, an 
endocytic trafficking factor involved in the processing of APP (188). 
 
1.2.3 The Amyloid Hypothesis 
The amyloid hypothesis was first proposed in 1991 (189-191) and is to date the most widely 
accepted hypothesis on the pathological processes behind AD, albeit not undisputed. 
According to this hypothesis it is the accumulation of b amyloid that is the driver of AD 
pathogenesis. This amyloid accumulation initiates other downstream processes, such as NFT 
formation, gliosis, loss of synapses and neuronal death, with the pathogenesis becoming 
increasingly complex and multifaceted as the disease progresses. There have also been 
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speculations around the possibility that amyloid accumulation and tau pathology might have a 
common upstream initiator that is currently unknown (192). 
The origins of the amyloid hypothesis hail from the discoveries of the pathogenic autosomal 
dominant mutations in APP, PSEN1 and PSEN2 (122, 124, 125). As a vast majority of these 
mutations have an effect on the relative or absolute levels of Ab42, or its propensity to 
aggregate, it seems logical to presume a causal relationship between Ab42 accumulation and 
the early development of AD pathology observed in carriers of these mutations. The discovery 
that many of the gene polymorphisms which increase the risk of AD, such as APOE e4, are 
involved in the processing of APP and/or the trafficking and clearance of Ab have further 
established the central role of Ab in AD pathogenesis. However, there are some who believe 
that the causality of AD is far more complicated and that Ab aggregation is neither necessary 
nor sufficient to start the pathological cascade of the disease. The observation that healthy 
adults can have substantial amounts of Ab plaques without any cognitive symptoms has been 
used as an argument in support of these views (193). Also, most clinical trials in AD patients 
involving monoclonal antibodies targeting Ab have up until now been unsuccessful in halting 
cognitive decline (194, 195). The fact that most of the subjects in these trials have been in the 
clinical stage of dementia has been suggested as an explanation for this lack of treatment effect, 
as the disease might be irreversible in the dementia stage. Currently, ongoing clinical trials on 
this treatment modality are mainly aimed at subjects with MCI or at subjects who are free of 
cognitive symptoms but have an increased genetic risk of developing AD and/or have 
biomarker signs of cerebral amyloidosis. A recent study on immunotherapy with aducanumab, 
a human monoclonal Ab antibody, involving patients with MCI and mild dementia due to AD, 
both showed a clearance of Ab plaques from the brain and a slowing of cognitive decline (196). 
Treatments intended to reduce the production of Ab42 through the inhibition of b-secretase 
also hold promise but are not as far along in development as immunotherapies. The amyloid 
hypothesis is therefore far from disproven and the clinical trials that are now underway will 
almost certainly shed a clearer light on its validity in the coming years.  
  
1.3 BIOMARKERS IN ALZHEIMER DISEASE 
Biomarkers that can be used in vivo are essential in mapping the chain of events in AD, from 
the preclinical stage to the clinical stage. The characterization of preclinical AD would not be 
possible without the use of biomarkers as no clinical symptoms have yet emerged. Biomarkers 
are also useful in selecting patients for clinical trials and for monitoring treatment effect. In the 
NIA-AA guidelines for AD diagnosis the clinical use of biomarkers is optional, but has still 
become widespread in the clinical setting, mainly as a supportive rather than a decisive tool. 
This includes the CSF biomarkers Ab42, total tau-protein (t-tau) and phosphorylated tau-
protein (p-tau), as well as FDG-PET, amyloid PET and structural MRI. These biomarkers 
reflect two of the hallmarks of AD, cerebral amyloidosis (CSF Ab42 and amyloid PET) and 
neurodegeneration (CSF t-tau and p-tau, FDG-PET and structural MRI). Experimental 
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biomarkers reflecting other pathological processes are under development, both as possible 
diagnostic aids and for further characterization of the natural history of AD. These include 
novel CSF biomarkers and PET ligands as well as blood based biomarkers (197) and 
electroencephalographic algorithms (198, 199).  
1.3.1 Biomarkers in the cerebrospinal fluid 
Three core CSF biomarkers, Ab42, p-tau and t-tau, have been extensively evaluated for use in 
AD diagnosis and research (200). CSF Ab42 reflects Ab aggregation and plaque formation, 
and decreases in AD to about 50% of control levels (200-202). When Ab42 was measured in 
both pre- and postmortem CSF from AD patients and patients with other neurological 
conditions, it correlated inversely with Ab plaque load on autopsy (203, 204). The same inverse 
correlation has been seen between CSF Ab42 levels and degrees of retention of the PET 
amyloid ligand Pittsburgh Compound B (PiB) (205-208) which signals brain amyloidosis. A 
decrease in CSF Ab42 has been observed in a few other conditions besides AD, such as 
dementia with Lewy bodies, a disorder also characterized by amyloid plaques, (209) and 
transiently in bacterial meningitis (210), probably due to degradation by proteases during the 
acute phase (211). This makes a decrease in CSF Ab42 not entirely specific to AD. Studies 
have shown that CSF Ab42 decreases early in the pathological cascade of AD and remains 
stable and low thereafter (212-215), making it an unsuitable marker of disease severity and rate 
of progression. CSF Ab42 has been shown to already be reduced in prodromal AD and even 
in the preclinical asymptomatic stage of AD (37, 38, 44, 216-218). The exact time point at 
which the CSF Ab42 reduction occurs, in relation to development of symptoms and changes 
in other biomarkers, still remains to be fully elucidated. However, CSF Ab42 reduction is 
considered to be upstream of most, if not all, other biomarker changes related to AD pathology 
(34, 202). 
The second AD CSF biomarker is p-tau which reflects tau phosphorylation and increases 
around 200% from control levels in AD, most likely before the onset of the prodromal stage, 
and remains steady and high thereafter (201, 202). Assays are available both for tau 
phosphorylated at threonine 181 (p-tau181) and at threonine 231 (p-tau231). These are considered 
to be equivalent in diagnostic accuracy (219), although there is a possibility that p-tau231 has a 
somewhat greater specificity for AD than p-tau181 (220). The increase in CSF p-tau has as of 
yet not been observed with certainty in other pathological conditions, making elevated p-tau 
seemingly exclusive to AD.  
The third, and final, core AD biomarker is t-tau which represents axonal degeneration and 
increases around 300% early in the course AD, probably around the same time as p-tau (201, 
202). T-tau is the least specific for AD of the three core CSF biomarkers, with increases in t-
tau being observed in other neurological conditions such as stroke, trauma, encephalitis and 
Creutzfeld-Jakob disease (221-224).  
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Combining all three core CSF biomarkers yields higher sensitivity and specificity for AD than 
can be achieved using only one or two of them. The combination of reduced concentration of 
Ab42 and high concentrations of p-tau and t-tau comprises the so called “AD signature” in 
CSF which has been shown to be highly predictive of progression to AD dementia in MCI 
patients (201, 225-229). An example of this is a study showing 95% sensitivity and 87% 
specificity of the “AD signature” in CSF in distinguishing between prodromal AD and stable 
MCI (229).  
However, there still are several obstacles that need to be overcome before incorporating CSF 
biomarkers into clinical diagnostic guidelines for AD. These include interassay, intralaboratory 
and interlaboratory variations, which currently are considered to be unacceptably high (202). 
International projects, e.g. Biomarkers for Alzheimer´s disease and Parkinsons´s disease 
(BIOMARKAPD) (230) and the International Federation of Clinical Chemistry and Laboratory 
Medicine Working Group for CSF proteins (IFCC WG-CSF) (231), are underway to address 
these issues and to facilitate the development of standard operating procedures regarding CSF 
collection and analysis as well as the development of fully automated instruments for CSF 
assays (232).  
There is great interest in developing novel CSF biomarkers reflecting other pathological 
processes than the core AD biomarkers, or other aspect of the same processes. The possible 
advantages of such development include further characterization of the natural history of AD, 
monitoring disease severity and possibly even treatment response, uncovering new treatment 
targets and increasing the sensitivity and specificity of AD diagnosis using CSF biomarkers. 
The Alzbiomarker database encompasses meta-analyses on original research on AD 
biomarkers (233), both in the CSF and in blood. Novel CSF biomarkers that have been the 
subject of studies over the past years and have shown some level of promise include truncated 
Ab species, sAPPa and sAPPb, Ab oligomers, neurofilament proteins, neurogranin, VLP-1, 
YKL-40, BACE1 concentration and activity and sTREM2 (233).  
 
1.3.2 Neuroimaging biomarkers 
1.3.2.1 Magnetic resonance imaging 
Structural neuroimaging is a required part of the clinical assessment of individuals with 
cognitive impairment. The purpose being to rule out causes for cognitive symptoms other than 
neurodegenerative diseases, e.g. cerebral infarction and neoplasms, and to assess the degree 
and localization of cerebral atrophy (234). Although a computerized tomography (CT) scan 
can suffice in some cases, magnetic resonance imaging (MRI) is the imaging method of choice 
in the diagnostic assessment of possible AD (234, 235). Evaluation of the hippocampus through 
high resolution T-1 weighted MRI is the best established and validated structural imaging 
marker in AD (236-240) with the medial temporal atrophy (MTA) score being widely used in 
the clinical setting to assess atrophy of the hippocampus (239, 241-243). Amyloid markers, 
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such as CSF Ab42 and amyloid PET, are considered to be more sensitive than structural MRI 
in the preclinical stage of AD (34), with structural MRI markers correlating more closely to 
disease progression in MCI and the earlier stages of AD dementia (244, 245). An example of 
this is the close correlation between atrophy rates of the whole brain (246-249), entorhinal 
cortex (250), hippocampus (251-253) and medial temporal lobe (254) on MRI and the 
progression of cognitive decline in AD. Functional MRI (fMRI) complements structural MRI 
by providing information on the functional integrity of brain networks, making it of great 
interest as a potential AD biomarker.  
1.3.2.2 Positron emission tomography 
There are two types of PET tracers which are most widely used in AD; FDG which indicates 
synaptic activity and amyloid tracers which reflect the accumulation of fibrillar amyloid plaque 
deposition (255). FDG is a glucose analog which gives a good indication of brain metabolism 
as glucose is the primary energy source of the brain (256). Decreased uptake of FDG is 
considered to be a marker of neurodegeneration and has a characteristic pattern in dementia 
due to AD, involving the precuneus, posterior cingulate gyri, inferior parietal lobule, 
posterolateral portions of the temporal lobe, hippocampus and medial temporal cortices (257-
260). Hypometabolism on FDG-PET has also been observed in patients with MCI (261, 262) 
as well as in cognitively healthy individuals with genetic risk for AD (38, 258, 263, 264). 
Despite these early pathological changes on FDG-PET, reduced FDG uptake is generally 
considered to occur downstream of increased brain amyloidosis detected by amyloid PET (34). 
Fibrillar amyloid; neuritic plaques and CAA in particular, can be detected through PET 
imaging with amyloid ligands including PiB, florbetapir, florbetaben and flutemetamol (235, 
265, 266). These ligands have all been shown to correlate closely with neuritic plaque load at 
autopsy and on cortical brain tissue biopsy (267-270) and their retention has good predictive 
value for the conversion from MCI to dementia due to AD (17, 207, 271, 272). An increase in 
amyloid load as detected on PET is an early event in AD and has been reported in asymptomatic 
carriers of FAD mutations as early has 15 – 20 years before the onset of the first clinically 
relevant cognitive symptoms (264, 273). An increase in brain amyloid burden has also been 
reported in cognitively healthy older adults who later progress to symptomatic AD (35, 274). 
Longitudinal studies have shown that the amyloid burden on PET increases in an almost linear 
fashion from the preclinical stage of AD through to the dementia stage, where it finally reaches 
a plateau (35, 245, 275) and does not correlate with disease severity in the later stages of the 
disease (276). Studies have shown a high level of concordance between increased amyloid PET 
signal and decreased levels of CSF Ab42 (205-208) and it remains unresolved which of these 
two biomarkers detects the earliest signs of amyloid accumulation. However, there are 
indications that the decrease in Ab42 in the CSF precedes the earliest detectable signs of 
retention of PET amyloid tracers (277).   
As with CSF biomarkers there are several issues concerning the clinical use of amyloid PET in 
AD diagnosis (266), including the fact that amyloid positivity on PET is a relatively common 
 30 
occurrence in cognitively healthy individuals (270, 278, 279). These individuals might be in 
the preclinical stage of AD, thereby explaining the amyloid positivity, but further longitudinal 
studies are needed to fully address this issue. There have also been reports of amyloid negativity 
on PET in symptomatic FAD patients (280). 
Other PET tracers have emerged in recent years, including [11C]-deuterium-L-deprenyl (DED), 
a ligand that binds to monoamine oxidase B (MAO-B) on the outer mitochondrial membrane 
in astrocytes and indicates reactive astrocytosis (281, 282). Tau specific tracers, such as 
THK5317, THK5351, AV-1451 and PBB3, are also under development (283). These tracers 
hold promise in the diagnosis of AD and other neurodegenerative diseases, as well as in further 
elucidating the relationship between cause and effect in their pathogenesis. 
The biomarkers presented above, both those that are well validated and others that carry 
potential, offer a unique opportunity to gain new insights into the sequence of events in 
preclinical AD. Cognitively asymptomatic carriers of FAD mutations are an ideal group for 
studying preclinical AD biomarker changes, as their expected symptom onset can be estimated 
and thereby the temporal relationship between biomarker changes and the onset of symptoms. 
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2 AIMS 
The overall aim of the studies incorporated in this thesis was to shed light on AD biomarker 
changes in Swedish carriers of FAD mutations in the preclinical stage of the disease. Results 
from studies involving FAD mutation carriers are generally believed to translate onto patients 
with the much more common sporadic form of AD, making their implications wider than if 
they only applied to FAD. Preclinical biomarker changes are an important subject to study, as 
biomarkers are essential in characterizing the preclinical stage of AD. Disease modifying 
therapies that are currently in clinical trials in AD are believed to be most effective when 
applied as early as possible in the disease process, preferentially before the onset of the first 
clinically relevant cognitive symptoms. Biomarkers are crucial in identifying asymptomatic 
individuals with underlying cerebral AD pathology, which are believed to benefit the most 
from the therapeutic interventions that are under development. Biomarkers can also have a role 
in monitoring disease progression and treatment response and in staging disease severity. 
Specific aims of each study: 
• To assess levels of the core AD CSF biomarkers Ab42, t-tau and p-tau and their 
correlation with years to symptom onset in asymptomatic carriers of FAD mutations, 
compared with non-carriers from the same families. To assess brain structure on MRI 
and its correlation with years to onset in the same population (paper I). 
• To assess the effects of different FAD mutations on APP processing in both preclinical 
and clinical AD, by measuring levels of CSF sAPPa, sAPPb, Ab42, Ab40 and Ab38 
in carriers of three different FAD mutations, and comparing them with non-carriers 
from the same families (paper II). 
• To summarize and interpret long-term clinical and biomarker data from a carrier of the 
PSEN1 H163Y mutation suspected of exhibiting reduced penetrance of the mutation 
(paper III). 
• To assess the CSF levels of YKL-40 and neurogranin, reflecting glial activation and 
synaptic degeneration respectively, in asymptomatic carriers of FAD mutations 
compared with non-carriers from the same families. Also, to assess the relationship 
between years to symptom onset and the levels of YKL-40 and neurogranin (paper IV). 
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3 SUBJECTS AND METHODS 
3.1 THE FAMILIAL ALZHEIMER DISEASE STUDY 
The Swedish FAD study was initiated at Karolinska Institutet in 1993 and has been ongoing to 
this day. Initially, the participants were recruited through the Memory Clinic at the Karolinska 
University Hospital in Huddinge and later through the Genetics Unit of the Memory Clinic in 
Huddinge. The researchers involved in the study have not taken primary contact with potential 
participants, the participants have either contacted the Genetics Unit on their own initiative or 
been approached by a relative. The participants come from four families, carrying four different 
FAD mutations, the Swedish APP double mutation (APPswe) KM670/671NL (123, 284), the 
arctic APP mutation (APParc) E693G (135), the PSEN1 H163Y mutation (164, 285) and the 
PSEN1 I143T mutation (286). The clinical phenotype of AD in each family has been described 
in detail in previous publications (286-288). A total of 69 individuals from these four families 
have participated in the study, some repeatedly, amounting to 169 separate study visits. 
The age at onset of the first clinically relevant cognitive symptoms in affected family members 
has been estimated after a retrospective review of the medical records of family members who 
had developed dementia before the study was initiated and a prospective clinical assessment in 
those who developed symptoms while enrolled in the study. Based on this the mean age at 
symptom onset in the families was calculated and reported to be 54 years with a standard 
deviation (s.d.) of ± 5 years for the APPswe mutation (based on 24 affected cases), 56 ± 3 years 
for the APParc mutation (based on 12 affected cases), 52 years ± 7 years for the PSEN1 H163Y 
mutation (based on 9 affected cases) and 36 years ± 2 years for the PSEN1 I143T mutation 
(based on 5 affected cases). These numbers, presented in paper I, changed slightly for the 
APPswe mutation carriers and the PSEN1 H163Y carriers in papers II – IV, where the average 
age at onset was reported to be 54 years ± 4 years for the APPswe mutation (based on 19 
affected cases) and 51 years ± 7 years for the PSEN1 H163Y mutation (based on 11 affected 
cases). The reason for this discrepancy is that a new review of medical records was conducted 
between papers I and II which resulted in 5 APPswe mutation carriers being excluded from the 
age at onset calculations due to insufficient data and 2 new PSEN1 H163Y mutation carriers 
being included as they had developed symptoms after the calculations for paper I were done.  
The FAD study is a prospective longitudinal study involving mutation carriers from the 
families described above, as well as non-carriers from the same families who serve as healthy 
controls. The participants and researchers involved in the study are blind to the mutation status 
of the participants, except for those who have requested presymptomatic or diagnostic genetic 
testing. Each study visit involves a thorough clinical evaluation, neuropsychological 
assessment, MRI of the brain, EEG, skin biopsy for collection of fibroblasts and collection of 
CSF, blood and saliva samples. Each participant also receives genetic counseling in 
conjunction with the study visits. Neuroimaging of the FAD family members with PET is 
conducted at the Section of Nuclear Medicine & PET at the University of Uppsala, in 
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collaboration with a research group at the Karolinska Institutet led by Professor Agneta 
Nordberg, but in close temporal conjunction with the other parts of the FAD study. 
3.2 SUBJECTS 
The demographic characteristics of the subjects involved in the cross-sectional parts of the 
studies constituting this thesis are presented in table 4. See paper IV for a description of the 
subjects in the longitudinal part of the paper IV study. Paper III is not represented in table 4 as 
there were only two participants in that study. There is a slight variability in the total number 
of participants between studies and in the distribution between mutation carriers and non-
carriers. One reason for this is that CSF samples acquired between 2006 – 2011 were included 
in paper I, while samples from 1993 – 2011 were included in paper II and samples from 1993 
– 2015 in paper IV. The samples from the 1990’s were included in papers II, III and IV after a 
stability assay of these frozen samples was performed and showed no signs of systematic time-
dependent changes. Paper IV includes the newest samples, taken in 2012 - 2015, most of which 
are a part of the longitudinal analysis in paper IV, i.e. from individuals who had already 
undergone a previous baseline sampling. Another reason is that some of the older frozen CSF 
samples were depleted when it came to the later studies.  
Only individuals with a first degree relative affected by FAD are included in the study, 
therefore all of the participants have a 50% risk of carrying a FAD mutation themselves. A 
small minority of the participants have opted for presymptomatic genetic testing, making a bias 
due to either MC or NC being more willing to participate highly unlikely. This natural “random 
assignment” of subjects to the MC or NC groups resulted in these groups being statistically 
comparable regarding the demographic variables presented in table 4; age, years to symptom 
onset, gender distribution and number of APOE e4 carriers. It is interesting to note that the MC 
and NC groups included in papers I, II and IV all have a relatively high prevalence of APOE 
e4 carriers, or around 50%, compared to the  ~ 25% prevalence of APOE e4 in the general 
population (178). The frequency of the APOE e4 allele has been determined specifically in 
different areas of Sweden and found to be ~ 20% (289), thereby excluding the explanation that 
the high prevalence in the FAD family members is due to a generally high prevalence in 
Sweden. 
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3.3 METHODS 
The methods applied in papers I – IV are described in the respective papers in detail. In the 
studies involved in this thesis the main focus was on CSF biomarkers, with neuroimaging 
biomarkers also included in papers I and III. 
3.3.1 Genetic analysis 
The researchers performing the genetic analysis did not have access to any data linking DNA 
samples to specific subjects. Blood was drawn from each subject on two separate occasions for 
DNA analysis to ensure the reliability of the results.  
3.3.1.1 Apolipoprotein E 
The APOE genotyping was performed for single nucleotide polymorphisms (SNPs) rs7412 and 
rs429358 using TaqMan®, SNP Genotyping Assays (ABI, Foster City, CA, USA) according 
to manufacturer’s protocol. The amplified products were run on a 7500 fast Real-Time PCR 
System (ABI, Foster City, CA, USA). 
3.3.1.2 Mutation analysis in APP and PSEN1 
Exons 16 and 17 in APP were sequenced to screen for the KM670/671NL (123) and the E693G 
mutations (135). To confirm the H163Y mutation in PSEN1 exon 6 was sequenced (164). 
Finally, exon 5 was sequenced to confirm the I143T mutation in PSEN1 (290). DNA was 
amplified using AmpliTaq Gold® PCR Master Mix (ABI, Branchburg, NJ, USA). Primer 
sequences and polymerase chain reaction (PCR) conditions are available upon request. Big 
Dye® terminator v3.1 Cycle sequencing Kit (ABI, Austin, TX, USA) was used for sequencing. 
The exons in APP and PSEN1 were sequenced in both directions and analyzed on an ABI3100 
Genetic Analyzer (ABI, Foster City, CA, USA). 
3.3.2 Neuropsychological assessment 
All of the participants underwent the same battery of 12 neuropsychological tests, employed 
by the same psychologist (from 1993 to the present day). The Information and Similarities tests 
(291) assessed verbal ability, the Block Design (291, 292) and Rey-Osterrieth copy (293) tests 
assessed visuospatial ability, Digit Span forward (291, 292) and Corsi Span (293) assessed 
immediate memory, Rey Auditory Verbal Learning total learning and 30 minutes retention as 
well as Rey-Osterrieth 30 minutes retention (293) tests assessed episodic memory, Trail 
making test part A (293) assessed attention; and Digit Symbol (291, 292) and Trail making test 
part B (293) assessed executive function. A measure of current global cognitive function was 
calculated using five tests: Information, Similarities, Block Design, Digit Span and Digit 
Symbol (291, 292). Premorbid global cognitive function was estimated using the Swedish New 
Adult Reading Test (NART) (294). All raw scores were converted to z-scores using a reference 
group of healthy adults from the Karolinska University Hospital at Huddinge (295).  
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3.3.3 CSF collection and analysis 
The CSF samples were obtained in the time period between 1993 and 2015. A lumbar puncture 
was performed in the L3/L4 or L4/L5 interspace with the patient in a sitting position and the 
CSF was collected into polypropylene tubes. Most of the CSF was collected between 9:00 and 
12:00, but on a few occasions, it was collected in the afternoon. Current evidence does not 
support a diurnal variation of either the core AD CSF biomarkers (296) or of YKL-40 and 
neurogranin (297). The participants received premedication with 1 g paracetamol and 5 mg 
diazepam prior to the procedure. Immediately after collection, the CSF was centrifuged at 3000 
x g at + 4°C for 10 minutes. The supernatant was pipetted off, aliquoted into polypropylene 
cryotubes and stored at -80°C. 
All of the biomarkers included in each of the studies were measured at the same time, using 
the same batch of reagents, at the Clinical Neurochemistry Laboratory at the Sahlgrenska 
University Hospital, Mölndal, Sweden by board certified laboratory assistants, blind to clinical 
data. All analytical procedures were performed according to protocols accredited by the 
Swedish Board for Accreditation and Conformity Assessment. 
CSF Aβ42, Aβ40 and Aβ38 were analyzed by the electrochemiluminescence technology 
(Meso Scale Discovery, Gaithersburg, Maryland, USA), using the MS6000 Human Abeta 3-
Plex Ultra-Sensitive Kit (the 6E10 version) (298). CSF total tau protein (T-tau) was determined 
using a sandwich enzyme-linked immunosorbent assay/ELISA (Innotest hTAU-Ag, Fujirebio 
Europe, Gent, Belgium) specifically constructed to measure all tau isoforms irrespective of 
phosphorylation status, as previously described (299), while P-tau (tau phosphorylated at 
threonine 181) was measured using the Innotest® phospho-tau 181P ELISA (Fujirebio Europe, 
Ghent, Belgium), as described previously in detail (300).  
The β-secretase cleaved soluble APP (sAPPβ) and α-secretase cleaved soluble APP (sAPPα) 
in CSF were analyzed using the MS6000 Human sAPPalpha/sAPPbeta Kit, following the 
recommendations by the manufacturer, and as described previously (301). The APPswe 
mutation changes the neo-epitope recognized by the capturing antibody in the sAPPβ assay, 
making sAPPβ measurements unreliable in APPswe MC. Therefore, the APPswe MC were 
excluded from the sAPPβ analysis in paper II. 
CSF neurogranin was measured using a sandwich ELISA, developed in-house at the 
Sahlgrenska Clinical Neurochemistry Laboratory as described previously in detail (302). CSF 
YKL-40 was measured using an YKL-40 ELISA kit, available from R&D Systems, 
Minneapolis, MN, USA.  
3.3.4 Neuroimaging acquisition, processing and analysis 
3.3.4.1 Magnetic resonance imaging 
The MRI image data sets included in paper I were acquired on a Siemens whole-body clinical 
MRI 3T scanner (Magnetom Trio, Erlangen, Germany) equipped with a 12-channel phase-
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array head coil. All of the participants underwent the same MRI protocol. A high-resolution 
3D T1-weighted MPRAGE sequence image (T1W1) was acquired in sagittal plane 
(TR/TE=1780/3.42ms, inversion time=900ms, 192 sagittal slices, voxel size 1×1×1mm3, and 
flip angle=9°). Full brain and skull coverage was required for the MRI datasets and detailed 
quality control was carried out on all MR images according to previously published quality 
control criteria (303). 
Cortical reconstruction and volumetric segmentation was performed using the FreeSurfer 5.1.0 
image analysis suite (http://surfer.nmr.mgh.harvard.edu/), including removal of non-brain 
tissue (304), intensity normalization (305), tessellation of the boundary between gray and white 
matter, surface deformation following intensity gradients to optimally place the gray/white and 
gray/cerebrospinal fluid borders at the location where the greatest shift in intensity defines the 
transition to the other tissue class (306, 307), registration to a spherical atlas (308) and creation 
of a variety of regional cortical and subcortical data. Results were visually inspected and 
manually edited if necessary in order to ensure accuracy of registration, skull stripping, 
segmentation and cortical surface reconstruction. 
After image processing, volume measures and cortical-based measures (thickness and volume) 
of relevant regions of interest (see papers I and III) were selected for analysis, normalized by 
the subject’s total intracranial volume (309). A circularly symmetric Gaussian kernel across 
the cortical surface was applied with a full width at half maximum (FWHM) of 15 mm to 
enable group analyses across the cortical mantle (paper I). 
In paper III the available longitudinal MRI data was clinically rated by an experienced 
neuroradiologist using the MTA scale (236) on coronal reconstructions of the T1 sequence. 
Briefly, the degree of atrophy is scored from 0 (no atrophy) to 4 (end-stage degree of atrophy) 
in the hippocampus, parahippocampal gyrus, entorhinal cortex and the surrounding 
cerebrospinal fluid spaces. The scores were then interpreted using age-adjusted cut-offs as 
detailed elsewhere (243). 
In this thesis, structural MRI results acquired as described above, are presented in papers I and 
III. Other parts of the FAD study have involved other MRI modalities, including diffusion 
tensor imaging and resting-state functional MRI to assess functional connectivity in the default 
mode network (310, 311).  
  
3.3.4.2 Positron emission tomography 
All PET examinations were performed at the Uppsala PET Centre, University of Uppsala, 
Sweden (see paper III for the timing of each PET examination in detail). The FDG scans from 
the 1990’s were acquired on a GEMS 2048-15B (General Electric Medical Systems, WI, USA) 
scanner or a GEMS 4096-15WB scanner. All subsequent acquisitions (FDG and PiB scans) 
were performed on an ECAT EXACT HR+ (Siemens/CTI) or a Discovery ST PET/CT 
(General Electric) scanner (312). The mean injected dose was approximately 3 MBq/Kg for 
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FDG, and 4 MBq/Kg for PiB. Sum images were created for both FDG (30-45 min) and PiB 
(40-60 min), and used for subsequent image analyses. 
For each modality and each participant, all the PET images were realigned and spatially 
normalized into a common MNI (Montreal Neurological Institute) space using a PET template 
(provided by SPM8 software) for FDG and a population-specific PiB-PET template (313) for 
PiB. 
A grey matter mask was applied to a simplified probabilistic atlas (314) consisting of 12 
bilateral regions of interest (ROIs). This atlas was then used for regional quantification of the 
PET tracers’ uptake, expressed in standardized uptake value ratio (SUVr) units with the pons 
as reference region, as it has been found to be a reliable reference for metabolism (315) and 
amyloid quantification (316) both in sporadic and familial AD. All PET quantification analyses 
were repeated using the cerebellar grey matter as reference region. All processing steps were 
performed using Matlab and SPM8. 
FGD- and PiB-PET data are presented in paper III of this thesis. There have been several other 
publications involving PET results from subjects in the FAD study, both using the 
aforementioned tracers and also involving the PET tracer DED (264, 312, 317). 
 
3.3.5 Statistical analysis 
The fact that FAD is a very rare disorder limits the number of individuals available for 
participation in studies on FAD and much of the literature on this disorder consists of small 
sample sizes. The study presented here is no exception, resulting in some statistical challenges 
due to the small number of participants.  
A detailed account of the statistical analysis is presented in each paper. In short, the groups of 
MC and NC were compared regarding age, years to onset, gender and number of carriers of the 
APOE e4 allele. The MC and NC groups were also compared regarding CSF biomarker levels, 
MRI measures and neuropsychological test measures. Finally, correlations were made between 
the levels of different CSF biomarkers in each group, as well as between the levels of CSF 
biomarkers, MRI and neuropsychological measures and years to onset.  
The D’Agostino-Pearson normality test was used to assess the distribution of different 
variables. Normally distributed variables were compared between the MC and NC using 
unpaired t test, while variables that were not normally distributed were compared between the 
groups using the Mann-Whitney U test. Pearson correlations were applied to normally 
distributed data, while Spearman correlations were applied to data that was not normally 
distributed. Fisher exact test was used to compare categorical variables between groups. In 
paper IV, linear mixed models were applied to the longitudinal CSF biomarker data, as well as 
ANOVA to compare the longitudinal biomarker levels between the MC and NC. 
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Correction for multiple comparisons was made when relevant using the Benjamini-Hochberg 
false discovery rate (FDR) procedure (318). 
3.3.5.1 Years to symptom onset calculations 
Years to symptom onset is a variable which is used frequently in papers I – IV. As described 
previously, symptom onset is the time point when a subject develops the first clinically relevant 
cognitive symptoms. The mean age at symptom onset has been calculated for each of the 
families participating in the FAD study (see section 3.1). Using the mean age at symptom onset 
in the family of a given asymptomatic subject, and the actual age of the person in question, one 
can calculate how many years this particular subject has left to symptom onset. An example of 
this could be a 47-year old individual (person A) from the APPswe family, where the mean age 
of symptom onset is 54 years: 
 Years to onset for person A = 47 years – 54 years = - 7 years 
This means that person A has 7 years left until expected onset of the first cognitive symptoms.  
Another example could be a 58-year old from the APPswe family (person B): 
 Years to onset for person B = 58 years – 54 years = 4 years 
Here the value for years to symptom onset is a positive one, i.e. person B is 4 years past the 
age of expected symptom onset. 
Calculating years to symptom onset provides a timeline for disease progression with the debut 
of cognitive symptoms as a reference point. Using years to symptom onset allows for the 
estimation of when, in relation to the development clinical symptoms, a given biomarker starts 
to change. This makes the calculation of years to onset relevant for both MC and NC, even 
though one does not expect the NC to develop symptoms, as it is important to use the same 
timeline and point of reference for comparing biomarker changes between the NC and the MC. 
 
 
3.4 ETHICAL CONSIDERATIONS 
Informed written consent was acquired from all participants prior to any procedure. All study 
procedures were approved by the Regional Ethical Review Board in Stockholm, Sweden and 
adhered to the Declaration of Helsinki. Additional informed written consent was obtained for 
publishing the case-report presented in paper III, both from the asymptomatic MC and from 
the son of his brother, as the brother had already passed away from AD. 
Obtaining informed consent from participants in studies on dementing illnesses can prove to 
be a challenge, as it can be unclear when a consent from a person with dementia is informed 
and when it is not. In the case of the Swedish FAD study the participants are recruited before 
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the onset of cognitive symptoms and can therefore be expected to understand the implications 
of their consent. When recruiting participants for a study on heritable diseases such as FAD, 
where disease modifying treatment is unavailable, it is also important to ensure that the 
researchers never take primary contact with possible participants, thereby making them aware 
of their increased genetic risk. The initiative must come from the subjects themselves, or their 
relatives, after they themselves have noticed that a particular illness runs in the family and want 
to know if there is a genetic cause. If a genetic cause is suspected, it is also important that the 
family members receive genetic counseling before, and in conjunction with, a search for a 
disease-causing mutation. The implications of finding such a mutation are wide and affect all 
members of the family, not just the one (or ones) seeking answers.  
That researchers involved in studies on possible mutation carriers remain blind to the mutation 
status of the study participants is of great importance, except in instances when the participant 
himself/herself is aware of their status. It is also important that family members are never 
pressured by researchers to opt for genetic testing of any sort, i.e. the initiative must come from 
the person in question after having received genetic counseling. The researchers must also 
make sure that the mutation status of individual subjects cannot be deducted from published 
data, e.g. by keeping demographic data on gender and age on a group level to avoid subjects 
being able to identify themselves as either an MC or an NC.   
Optimally, a study on individuals at risk for developing an illness such as early-onset AD 
should include counseling and psychosocial support for the study participants. Participants in 
the Swedish FAD study have all been offered such support in conjunction with their study 
visits. Interviews with a counselor involved in the study have emphasized the need for such 
support, especially for female participants, for those who have not yet passed the age at 
expected symptom onset and for spouses of individuals at risk (319, 320).  
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4 RESULTS 
4.1 CSF BIOMARKERS 
4.1.1 Absolute levels 
The absolute levels of the CSF biomarkers included in the thesis are summarized in figure 4. 
4.1.1.1 Ab42, t-tau and p-tau 
In paper I, the core AD biomarkers Ab42, t-tau and p-tau were measured in 10 asymptomatic 
MC who were 47 years old on average and had a mean of 7 years left till the onset of clinical 
symptoms. The biomarker levels in the MC were compared to the levels of the same biomarkers 
in a group of 12 NC with a mean age of 48 years and a mean of 7 years left to the onset of 
symptoms. The levels of Ab42 were significantly lower in the MC than the NC (729 ng/L vs. 
1687 ng/L, p = 0.0004), while the levels of t-tau and p-tau were significantly higher in the MC 
than the NC (533 ng/L vs. 294 ng/L, p = 0.03 and 63 ng/L vs. 43 ng/L, p = 0.03, respectively). 
Here, the ratio of Ab42 to p-tau was also compared between the MC and NC and found to be 
significantly lower in the MC (16 vs. 41, p = 0.002).  
4.1.1.2 sAPPa, sAPPb, Ab38, Ab40 and Ab42 
The APP processing products sAPPa, sAPPb, Ab38, Ab40 and Ab42 were measured and 
compared between a group of 19 MC and 17 NC in paper II. The APPswe mutation carriers 
were excluded from all the analyzes of sAPPb, both as a part of the MC group as a whole and 
as an APPswe subgroup, due to the fact that the end-specific capture antibody in the sAPPb 
assay does not react with sAPPb modified at positions 670/671 by the APPswe mutation.  
The MC had a mean age of 47 years and a mean of 8 years left to the onset of symptoms, while 
the NC were 49-years old on average and had a mean of 7 years left to symptom onset. The 
MC group included subjects with an MCI diagnosis (n=3) and subjects with a diagnosis of 
dementia due to AD (n=3). There was no difference in the levels of sAPPa, sAPPb or 
sAPPa/sAPPb  when comparing the MC to the NC. However, all of the measured Ab species, 
Ab38, Ab40 and Ab42, were significantly lower in the MC group. Also, the Ab2/Ab40 ratio 
was significantly lower in the MC than the NC (0.05 vs. 0.11, p < 0.0001). 
The calculations above were repeated after excluding all of the symptomatic MC, with the 13 
remaining MC having a mean age of 42 years and an average of 12 years left to symptom onset. 
There was still no significant difference between the MC and NC on any of the demographic 
variables after excluding the symptomatic MC. The exclusion of the symptomatic MC did not 
change the biomarker results presented above, except for the levels of Ab38 which were no 
longer significantly lower in the MC group. 
Finally, the MC were divided into subgroups of MC by mutation, i.e. into a group of APPswe 
carriers, APParc carriers and PSEN1 H163Y carriers (see table 5 for a summary of the direction 
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of the results). Here, the APPswe carriers had significantly lower levels of sAPPa and Ab42 
than the NC, but there was no difference in the levels of Ab38 and Ab40 between the APPswe 
carriers and the NC. The APParc carriers only had low levels of Ab42 compared to the NC, 
but there were no differences in the levels of Ab38 and Ab40 when comparing the APParc 
carriers and the NC. The APParc carriers and the NC had comparable levels of sAPPa, but 
sAPPb was significantly higher in the APParc carriers than in the NC. Finally, the PSEN1 
H163Y carriers had low levels of Ab42 and Ab38 compared to the NC, but there was no 
difference between the PSEN1 H163Y carriers and the NC in the levels of Ab40, sAPPa or 
sAPPb. The ratio of Ab42/ Ab40 was significantly lower in all the MC subgroups than in the 
NC but there was no difference between any of the MC subgroups and the NC regarding the 
ratio of sAPPa/sAPPb. These calculations were repeated after exclusion of symptomatic MC 
with no change to the results, except that the levels of Ab40 were significantly lower in the 
asymptomatic PSEN1 H163Y carriers than the NC. 
The low levels of Ab38 in the whole MC group and the PSEN1 H163Y carrier subgroup did 
not survive correction for multiple comparisons and neither did the low levels of Ab40 in the 
whole MC group.  
 
 APPswe APParc PSEN1 H163Y 
sAPPa ¯ « « 
sAPPb  ­ « 
Ab38 « « ¯ 
Ab40 « « « 
Ab42 ¯ ¯ ¯ 
Table 5. Direction of changes in the levels of the APP processing products sAPPa, sAPPb, Ab38, Ab40 
and Ab42 in the CSF of carriers of the APPswe, APParc and PSEN1 H163Y mutations, compared to 
NC. Levels of sAPPb were not available for the APPswe carriers. CSF, cerebrospinal fluid; NC, non-
carriers. 
 
4.1.1.3 YKL-40 and neurogranin 
Paper IV included 14 MC (with a mean age of 43 years and a mean of 12 years left to symptom 
onset) and 17 NC (with a mean age of 46 years and a mean of 9 years left to symptom onset). 
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All of the participants in the study presented in paper IV were asymptomatic at baseline. There 
was no significant difference in the baseline levels of YKL-40 when comparing the MC to the 
NC. Due to depletion of some of the CSF samples included in paper IV neurogranin levels 
were only available from 11 MC and 14 NC. The levels of neurogranin were not significantly 
different between the two groups.  
4.1.1.4 The outlier 
During the study presented in paper I the presence of an outlier in the MC group came to our 
attention. This person had opted for a presymptomatic genetic test, which made his mutation 
status known to himself and to the researchers involved in the study. Even though he had passed 
the age at symptom onset in his family he was showing no signs of cognitive decline and had 
normal levels of the core AD biomarkers in the CSF. The statistical analyzes of biomarkers in 
the MC and NC in paper I and in subsequent papers were done with and without this outlier. 
Excluding him had no effect on the results of any of the different analyzes in any of the papers. 
The results in paper I are presented with and without the outlier, while the results presented in 
papers II and IV are only presented without the outlier.   
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4.1.2 Correlations between different biomarkers 
In paper II, correlations were made between the levels of sAPPa, sAPPb, Ab38, Ab40 and 
Ab42. The APParc carriers were not included in the correlation calculations as a subgroup due 
to their small numbers (n=4) and as previously stated no data was available on sAPPb in the 
APPswe carriers due to technical limitations. There was a positive and significant correlation 
between sAPPa and sAPPb in both the MC and the NC, but not in the PSEN1 H163Y 
subgroup. There also was a significant and positive correlation between Ab38 and Ab40 in all 
groups and between Ab40 and Ab42 in the MC, NC and in the APPswe subgroup. In the NC 
group there were positive correlations between sAPPa and all three Ab species, but no such 
correlations were observed in the MC or the PSEN1 H163Y subgroup. Finally, the NC group 
showed a positive correlation between Ab38 and Ab42, which was not seen in the MC or in 
the MC subgroups.  
In paper IV, correlations were made between YKL-40 and neurogranin vs. the core AD 
biomarkers Ab42, t-tau and p-tau. YKL-40 correlated positively and significantly with all three 
core AD biomarkers in the NC and with all but Ab42 in the MC. The exact same pattern 
emerged for neurogranin, which correlated positively with Ab42, t-tau and p-tau in the NC and 
with t-tau and p-tau in the MC. 
All of the significant correlations presented above survived a correction for multiple 
comparisons.  
4.1.3 Correlations with years to symptom onset 
Correlations between CSF biomarkers and years to onset were made in papers I, II and IV. In 
paper I there was a trend of decreasing Ab42 and Ab42/p-tau ratio in the MC with approaching 
onset, while there was a trend of increasing t-tau and p-tau. The same trends were not observed 
in the NC. When comparing the MC to the NC, Ab42 seemed to start decreasing in the MC 
around 20 years from symptom onset, the Ab42/p-tau ratio around 15 years from symptom 
onset and t-tau and p-tau about 5 years from onset (see figure 5).  
The correlation between the APP processing products sAPPa, sAPPb, Ab38, Ab40 and Ab42 
and years to symptom onset was analyzed in paper II. There was no significant correlation 
between any of the aforementioned biomarkers and years to onset in either the MC group, NC 
group or the PSEN1 H163Y subgroup. In the MC group however, there was a trend of sAPPa 
and Ab42 decreasing with approaching symptom onset. Ab38, Ab40 and Ab42 decreased 
significantly in the APPswe carriers when the onset of symptoms approached and beyond. 
These correlations lost their significance when APPswe carriers with a dementia diagnosis were 
excluded, apart from the decrease in Ab42 which remained significant (r = - 0.85, p = 0.03), 
see figure 6.  
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Figure 5. Relationship between the core AD biomarkers and years to symptom onset. The solid lines 
represent Spearman correlations, while the dashed lines represent 95% confidence intervals (CI´s) for 
the correlations.  
 
 
 
Figure 6. Correlations between years to onset and the levels of Ab38, Ab40 and Ab42 (in ng/L) in 
carriers or the APPswe mutation. All three correlations were significant, Aβ38 (r=-0.69, p=0.04), Aβ40 
(r=-0.67, p=0.05) and Aβ42 (r=-0.86, p<0.01), decreasing in subjects sampled closer to the expected 
onset. 
APPswe: Correlations between years to onset and Aβ species
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In paper IV, YKL-40 and neurogranin were correlated with years to onset in asymptomatic MC 
and NC. YKL-40 correlated significantly and positively with years to onset in both the MC and 
the NC, while no correlation was found between neurogranin and years to onset in either the 
MC or the NC group. These results (as the others presented above) were obtained from cross-
sectional data. When the cross-sectional levels of YKL-40 and neurogranin were correlated 
with years to onset and plotted in a graph in the same way as the core AD biomarkers in paper 
I (see figure 5) it was not possible to visually gauge a separation between the MC and NC 
curves for YKL-40 (figure 7). 
 
 
Figure 7. Correlations between YKL-40 and years to onset in MC and NC. The solid line represents 
the correlation between YKL-40 and years to onset in the MC (r = 0.6817, p = 0.007) while the dotted 
line represents the same correlation in the NC (r = 0.6007, p = 0.01). The dashed lines represent the 95% 
CI´s for the correlations.  
4.1.4 Longitudinal analysis 
Follow-up samples were available to allow for a longitudinal analysis of the CSF biomarkers 
YKL-40 and neurogranin in paper IV. YKL-40 was analyzed in longitudinal samples from 9 
MC and 5 NC with a mean of 5 and 6 years from baseline till the first follow-up sampling 
respectively. Ten of these participants had one follow-up sample, while 4 participants had two 
follow-up samples. At the first follow-up sampling occasion four of the MC had developed 
MCI and at the second follow-up sampling occasion one more MC had developed MCI.  
Neurogranin was analyzed longitudinally in 8 of the 9 MC and in all of the 5 NC, as one of the 
MC samples did not suffice to analyze neurogranin as well. 
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There was a significant positive correlation between the longitudinal YKL-40 levels and years 
to onset (F = 25.1, p < 0.001) and the curve was steeper for the MC than for the NC (F = 5.54, 
p < 0.03).  
4.2 NEUROIMAGING BIOMARKERS 
MRI of the brain was included in paper I, where cortical thickness and volumetric measures 
were compared between a group of 13 MC and 20 NC. The mean age of the MC was 43 years, 
with a mean of 9 years left to symptom onset, while the mean age of the NC was 50 years, with 
a mean of 3 years left to symptom onset. After FDR correction for multiple comparisons there 
remained a significant decrease in the volume of the left precuneus, left superior temporal gyrus 
and left fusiform gyrus in the MC (see figure 8). There were no significant differences between 
the MC and NC regarding cortical thickness in either hemisphere or volumes in the right 
hemisphere. There were no significant correlations between the MRI variables and years to 
symptom onset in the MC. None of the aforementioned results changed after exclusion of the 
statistical outlier presented earlier in the results chapter.  
 
Figure 8. Regions in the left hemisphere with reduced volume in the MC are indicated in color. 1) Left 
hemisphere, medial surface; 2) Left hemisphere, lateral surface; 3) Left hemisphere, ventral surface; p: 
posterior; a: anterior. Brains are “inflated” in the three images to better represent the regions inside the 
sulci. Red-yellow represents less volume in the MC and blue represents more volume in the MC (see 
paper I for Talairach coordinates of the areas with decreased volume in the MC). 
 
4.3 NEUROPSYCHOLOGICAL ASSESSMENT 
In paper I, a neuropsychological assessment was performed on all 35 participants within 3 
months of the other examinations. The z-scores of the MC in five cognitive domains; verbal, 
visuospatial, immediate memory, episodic memory and attention/executive function, were 
compared with the z-scores of the NC. There were no significant differences between the MC 
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and the NC in any of the five domains, however there was a trend of poorer results in the MC 
regarding immediate memory, episodic memory and attention/executive function (see paper I). 
In the MC group, there were significant and negative correlations between years to onset and 
three cognitive domains; visuospatial (r = - 0.54, p < 0.05), episodic memory (r = -0.70, p < 
0.01) and attention executive function (r = -0.61, p < 0.05). In the NC, the same significant and 
negative correlation was seen regarding years to onset and attention/executive function (r = - 
0.50, p < 0.05). 
 
4.4 BIOMARKERS IN PAPER III 
In paper III, biomarkers in the CSF (Ab42, t-tau and p-tau) and neuroimaging biomarkers 
(MRI, FDG-PET and PiB-PET) as well as neuropsychological tests were combined to 
characterize a case of reduced penetrance of the PSEN1 H163Y mutation. This case came to 
our attention during the preparation of paper I, where a carrier of the PSEN1 H163Y mutation 
who was aware of his mutation status, turned out to be a statistical outlier in the MC group with 
normal levels of the core AD CSF biomarkers, despite having passed the mean age at symptom 
onset in his family. This outlier, as well as his brother who was one year older and also a 
mutation carrier, were a part of the FAD study over a period of 22 years. During this period 
both brothers underwent multiple clinical assessments and biomarker collections (see paper 
III). The outlier was 65 years old at the end of follow-up (in 2017), 14 years older than the 
mean age at symptom onset in his family, and did not show any signs of cognitive decline. He 
had normal levels of CSF Ab42, t-tau and p-tau at the age of 54, no signs of atrophy in the 
medial temporal lobe on MRI at the age of 57 and no definite signs of increased PiB retention 
on PET at the age of 60. His brother was diagnosed with MCI at the age of 55 and dementia 
due to AD a year later, at the age of 56. He showed typical biomarker signs of AD in the CSF, 
on MRI, FGD-PET and PiB-PET and a curvilinear decline in cognitive function on repeated 
neuropsychological tests. He was admitted to a nursing home due to dependence on others for 
all activities of daily living and died there at the age of 64. On autopsy, he fulfilled the 
neuropathological criteria for definite AD.  
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5 DISCUSSION 
5.1 PAPER I 
The AD biomarker studies in papers I, II and IV all showed significant changes in CSF and 
neuroimaging biomarkers in the preclinical stage of FAD. In paper I, which only included 
presymptomatic MC, CSF Ab42 was decreased and CSF t-tau and p-tau increased in MC who 
had a mean of 7 years left till the onset of symptoms. In this study the MC (with a mean of 9 
years till symptom onset) also had decreased volume of the left precuneus, left superior 
temporal gyrus and left fusiform gyrus on MRI and a trend of poorer results than the NC on 
neuropsychological tests assessing immediate memory, episodic memory and 
attention/executive function. Despite the relatively small number of participants in the study 
the biomarker changes in the MC were robust enough to show a significant separation from the 
NC, as early as 7 – 9 years before the expected onset of symptoms.  
When the CSF biomarkers were correlated with years to onset there was a trend of Ab42 and 
the Ab42/p-tau ratio decreasing and t-tau and p-tau increasing as the symptom onset 
approached in the MC, but not in the NC. The 95% CI’s for these trends showed a separation 
between the Ab42 curves of the MC and NC around 20 years before symptom onset, the 95 % 
CI’s for the Ab42/p-tau ratio separated around 15 years before symptom onset and around 5 
years before symptom onset for t-tau and p-tau. These results are merely trends which are based 
on cross-sectional data and do not allow for an exact estimation of the time point at which a 
given CSF biomarker starts to change in MC in the preclinical stage of AD. However, they 
give an indication of the temporality of these changes which warrants further study.  
The findings presented above have been corroborated in studies involving different populations 
of FAD MC. Generally, CSF Ab42 seems to be the biomarker to show the earliest changes in 
preclinical FAD, followed by an increase in t-tau and p-tau some years later, sometimes years 
before the onset of symptoms and sometimes coinciding with them (38, 321, 322). A recent 
study on cognitively healthy carriers of the APOE e4 allele also showed a decline in CSF Ab42 
starting about a decade before a similar decline in non-carriers (323). Interestingly, the studies 
on CSF biomarkers in cognitively healthy individuals at increased genetic risk for developing 
AD have not been entirely unequivocal. A study on young carriers of the PSEN1 E280A 
mutation showed an increase in CSF Ab42 which was observed 20 years before the expected 
onset of symptoms (36). This might be due to increased Ab42 production, initially reflected in 
high Ab42 levels in the CSF, which later would be expected to plummet due to aggregation of 
Ab42 in the brain. 
Structural MRI biomarkers in preclinical FAD have been extensively studied with somewhat 
variable results. One study reported a decrease in bilateral hippocampal volumes in 
asymptomatic MC 15 years before the expected onset of symptoms (38) while another study 
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found the same atrophic changes 6 years before onset (321). Hippocampal atrophy in MC 
starting even closer to the onset of symptoms has also been reported, with the atrophy being 
more pronounced on the left side (324). Yet another study found no cortical thinning or 
hippocampal atrophy in non-demented MC (325). Finally, a longitudinal study on hippocampal 
and whole brain atrophy rates in FAD found both rates to be increased in MC 5.5 and 3.5 years 
prior to AD diagnosis respectively (326). In the study presented in paper I we found no 
hippocampal atrophy when comparing the presymptomatic MC to the NC. This might be due 
to a true absence of atrophy in this area in our study group, but this might also be due to other 
factors such as the relatively small sample size. Another possible explanation could be that 
even though the difference in mean years to symptom onset was not significant between the 
MC and NC (9 years vs. 3 years), the fact that the NC were 6 years closer to symptom onset 
could have masked some differences between the groups.  
The areas in which the MC displayed increased atrophy on MRI in paper I, the left precuneus, 
left superior temporal gyrus and left fusiform gyrus, are generally in agreement with areas of 
atrophy reported in other studies. In a study comparing early-onset AD to late-onset AD the 
patients with the early-onset exhibited grey matter atrophy in the hippocampus, temporal lobes, 
precuneus, cingulate gyrus and inferior frontal cortex, while the atrophy was most pronounced 
in the hippocampus, right temporal lobe and cerebellum in the patients with late-onset (327). 
In a longitudinal study on FAD focusing on other ROI’s besides the hippocampus a decrease 
was reported in the cortical thickness of the precuneus in MC 4.1 years prior to AD diagnosis 
(328).  These results are in agreement with our observation of decreased volume of the left 
precuneus in the presymptomatic MC in paper I. The precuneus, along with the posterior 
cingulate and temporoparietal regions, have been shown to have an increased cortical thickness 
and volume in carriers of FAD mutations with a mean of 16 years left to symptom onset. A 
longitudinal part of this same study showed an increase in the rate of cortical thickness loss in 
the precuneus-posterior cingulate and superior parietal, right lateral temporal and left 
orbitofrontal, and middle frontal regions in the presymptomatic MC (329). These results might 
imply an initial increase in volume and cortical thickness due to inflammation and/or 
accumulation of Ab, followed by atrophy in the same areas (329, 330). Finally, the asymmetry 
in our findings, with the significant volume reduction in the MC being limited to the left 
hemisphere, both regarding the precuneus and areas in the temporal lobe, does not come as a 
surprise. Several studies on AD have shown earlier signs of cortical atrophy in the left 
hemisphere than the right, as well as faster rates of atrophy progression on the left side (331, 
332). 
5.2 PAPER II 
In paper II we assessed CSF levels of sAPPa, sAPPb, Ab38, Ab40 and Ab42, all products of 
APP processing. Even though most of the MC in this study were asymptomatic we also 
included three MC with an MCI diagnosis and a further three with a diagnosis of dementia due 
to AD. We then divided the MC into subgroups, both a presymptomatic subgroup and 
subgroups of MC carrying the same mutation (APPswe, APParc or PSEN1 H163Y). In contrast 
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to the biomarkers in paper I, which only included presymptomatic MC, the biomarkers in paper 
II have been much less extensively studied (apart from Ab42) and we therefore found it of 
interest to also include symptomatic MC in paper II. Furthermore, dividing the MC into 
subgroups by mutation was more interesting in this case, as each of these three mutations is 
believed to affect the processing of APP differently. This was done with full awareness of the 
fact that each MC subgroup would be very small which would lead to the results having to be 
interpreted with caution. The APParc group only included 4 MC and therefore no correlation 
calculations were made solely in that group. Finally, no analysis was made on the levels of 
sAPPb in the APPswe carriers, as the APPswe mutation changes the neo-epitope which is 
recognized by the capturing antibody of the sAPPb assay, making the results of this assay 
unreliable in the case of these particular MC. 
Before the analyzes of the APP processing products were made we hypothesized that each of 
the three mutations included in the study would have a different effect on their levels. The 
APPswe mutation is located in APP, at the cleaving site of BACE1, and is believed to increase 
the affinity of BACE1 for the mutated APP. Therefore, we assumed that the mutation would 
cause an increase in sAPPb, Ab38, Ab40 and Ab42 (all products of the amyloidogenic pathway 
of APP processing in which BACE1 is involved) and a decrease in sAPPa. The APParc 
mutation is located within the Ab sequence of APP and increases the propensity of Ab to form 
fibrils. This mutation would not be expected to affect the levels of sAPPa or sAPPb, but 
decrease the levels of Ab42 (and possibly also of Ab38 and Ab40), due to accelerated fibril 
formation. Figure 2 illustrates the locations of the APPswe and APParc mutations in the APP 
sequence. Finally, the PSEN1 H163Y mutation is located in the third transmembrane domain 
of the g-secretase and causes the g-secretase to preferentially produce Ab42 at the expense of 
Ab40, thereby increasing the Ab42/Ab40 ratio, but not the overall production of Ab. Here we 
would expect to see normal levels of sAPPa and sAPPb and low levels of Ab38 and Ab40, 
due to a shift towards the production of Ab42. It is well known that the levels of Ab42 in the 
CSF are inversely related to the levels of Ab accumulation in the brain and this makes the 
interpretation of CSF Ab42 levels quite challenging. That is, low Ab42 levels in the CSF do 
not necessarily reflect low Ab42 production. This could also apply to the other Ab species 
studied in paper II and should be kept in mind when interpreting the results.  
When all of the MC were compared to the NC in paper II the MC had significantly lower levels 
of Ab38, Ab40 and Ab42 than the NC. No difference was found in the levels of sAPPa or 
sAPPb when comparing the MC to the NC. The results were the same after excluding the six 
symptomatic MC, except for the levels of Ab38, which were no longer significantly lower in 
the MC. Finally, the lower levels of Ab40 and Ab38 in the whole MC group did not survive 
an FDR correction for multiple comparisons. Therefore, the whole MC group only displayed 
low levels of Ab42, with no significant difference between them and the NC regarding the 
other APP processing products. One could argue that an FDR correction increases the risk of a 
type II error in this case, as the sample is very small and the number of comparisons between 
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the groups is limited and hypothesis driven. Therefore, it is not impossible that a true difference 
in Ab38 and Ab40 levels exists between the whole MC group and the NC. The Ab42/Ab40 
ratio was also compared between the MC and the NC and perhaps not surprisingly was found 
to be significantly lower in both the MC group as a whole, and the MC subgroups, than in the 
NC. These significant differences remained significant after excluding the symptomatic 
mutation carriers, supporting the role of the Ab42/Ab40 ratio as a robust biomarker of early 
AD pathology. 
When comparing only the APPswe carriers to the NC they had significantly lower levels of 
sAPPa and Ab42 than the NC (see table 5 for a summary of the changes in the APP processing 
products in each subgroup of MC). The decreased levels of Ab42 are as expected in carriers of 
FAD mutations in general, as Ab42 is known to be low in the CSF early in the AD disease 
process. The low sAPPa levels, which have also been shown to be low in a previous study on 
some of the same APPswe carriers (333), could be due to a shift towards the amyloidogenic 
pathway of APP processing, at the expense of the non-amyloidogenic pathway of which sAPPa 
is a product. The APParc carriers also showed the expected decrease in Ab42 as well as an 
increase in sAPPb, but there was no difference in the levels of Ab38 and Ab40 when comparing 
the APParc carriers to the NC. This does not support the hypothesis that the mutated Ab38 and 
Ab40 have an increased propensity to form fibrils, in the same way as the mutated Ab42, as 
Ab38 and Ab40 would then be expected to be scarce in monomeric form and their levels low 
in the CSF. The increase in sAPPb does come as somewhat of a surprise, as the APParc 
mutation is not believed to have an effect on the balance between the amyloidogenic and non-
amyloidogenic pathways of APP processing. One could speculate that a relative shortage of 
Ab42, due to the accelerated fibril formation, can increase the activity of the amyloidogenic 
pathway causing an increase in sAPPb production. Finally, the PSEN1 H163Y carriers had low 
levels of Ab38 and Ab42, but normal levels of the other APP processing products. The low 
Ab38 levels did not survive a correction for multiple comparisons, however there is a definite 
trend of Ab38 being lower in the PSEN1 H163Y carriers than in the other mutation carriers 
and the NC (see figure 4). As stated previously, the results from in vitro studies do not suggest 
that the PSEN1 H163Y mutation affects the balance between the amyloidogenic and non-
amyloidogenic pathways, making the findings of normal sAPPa and sAPPb levels as expected. 
The low Ab42 levels are also as expected and the low Ab38 levels as well, with the latter 
possibly due to a loss of function of the mutated g-secretase, causing it to be less able to cleave 
APP sufficiently often to produce a short Ab species like Ab38. Another possible explanation 
could be that Ab38 is accumulating in the brain, causing a shortage in the CSF, as amyloid 
plaques including Ab38 deposits have been demonstrated in FAD cases (334). 
When looking at the sAPPb/ sAPPa ratio, no significant differences emerged when comparing 
the MC, or the subgroups of APParc and PSEN1 H163Y carriers, to the NC. The sAPPb/ 
sAPPa ratio has been suggested as a biomarker of brain amyloidosis (335), but our results do 
not support this, at least not that the sAPPb/ sAPPa ratio can serve as a marker of early 
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pathology. The correlation between sAPPb and sAPPa was significant and positive in both the 
MC and the NC, which indicates that the amyloidogenic pathway and the non-amyloidogenic 
pathway are noncompetitive. These findings of a positive correlation between sAPPb and 
sAPPa have been reported in several previous studies on subjects with MCI, FAD and SAD 
(335-340). The positive correlation between sAPPb and sAPPa, and the assumed 
noncompetitiveness of the two APP processing pathways, can possibly explain the failure of 
the sAPPb/ sAPPa ratio do differentiate between the MC and the NC. When looking at 
correlations between the three Ab species on one hand and sAPPb and sAPPa on the other 
hand we found that all three Ab species were positively correlated to sAPPa in the NC. This 
might seem counterintuitive as sAPPa and the Ab species are not products of the same APP 
cleaving pathway. However, high levels of Ab species in the CSF, at least of Ab42, are 
considered to reflect an absence of brain amyloidosis, and sAPPa could also be expected to be 
higher in individuals without Ab accumulation in the brain than in patients with preclinical 
AD.  The Ab species were then correlated with each other, revealing a positive correlation 
between Ab38 and Ab40 and between Ab40 and Ab42 in both the MC and the NC. This 
suggests that a decrease in one Ab species in the CSF is accompanied by a decrease in the 
others. Based on this one can speculate that when the threshold for Ab accumulation in the 
brain is reached it involves all of the Ab species measured here, which then aggregate in the 
brain parenchyma and vasculature, causing a reduction of their levels in the CSF. 
In the final part of paper II, sAPPa, sAPPb, Ab38, Ab40 and Ab42 were correlated with years 
to onset in the MC, NC and the MC subgroups. There was no difference between the levels of 
sAPPa and sAPPb in the MC and the NC and no change was seen in these markers related to 
proximity to symptom onset.  The levels of Ab38, Ab40 and Ab42 were lower in the MC than 
in the NC, but did not decrease as onset approached, perhaps as they had already become 
relatively stable at their low levels in the MC. The only significant correlations between the Ab 
species and years to onset were seen in the subgroup of APPswe carriers, consisting of 9 
individuals, of whom 2 had an MCI diagnosis and 3 had a dementia diagnosis. These 
correlations ceased to be significant for Ab38 and Ab40, but not for Ab42, after exclusion of 
the subjects with dementia. These findings indicate that a decrease in Ab38 and Ab40 levels 
might be most pronounced in the symptomatic stages of AD, but only longitudinal studies 
involving more subjects can determine if this is in fact the case. This resonates somewhat with 
a study on several CSF biomarkers, including sAPPa, sAPPb and Ab40, which showed a 
decrease in these markers in patients in the advanced stages of clinical AD (341). Therefore, 
there is a possibility that sAPPa, sAPPb and Ab40, as well as Ab38, can serve as markers of 
disease severity rather than as early diagnostic markers.  
5.3 PAPER IV 
There is a large interest in developing novel CSF biomarkers for AD, both early diagnostic 
markers and markers of disease progression and severity. In paper IV we included two such 
markers, YKL-40 and neurogranin, which represent different pathophysiological processes 
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believed to have an involvement in AD. YKL-40 is a glycoprotein, also known as chitinase-3-
like protein, which is expressed by several cell types, including glial cells and neurons in the 
central nervous system (CNS) (342-344). The functions of YKL-40 have not yet been fully 
elucidated, but include the regulation of inflammatory responses (345), promotion of cell 
proliferation and migration (346) and enhancement of tumor growth, angiogenesis and 
macrophage infiltration (347). Neurogranin is a calmodulin-binding protein, found mainly in 
the dendritic spines of neurons in the association cortex of the brain (348, 349). It is a 
postsynaptic protein involved in synaptic plasticity and is believed to be able to serve as a 
synaptic marker (350, 351). Both YKL-40 and neurogranin have been shown to be able to 
differentiate between patients with dementia due to AD and healthy controls (352-362) as well 
as between subjects with stable MCI and subjects with MCI who later develop dementia (354, 
358, 361-363). 
The study presented in paper IV was the only biomarker study in this thesis to include 
longitudinal data as well as cross-sectional data. Only presymptomatic subjects were included 
in the cross-sectional part of the study, while five of the MC in the longitudinal part of the study 
developed MCI during follow-up. Due to some of the samples being low in volume, a few 
samples were depleted after the YKL-40 assay, resulting in YKL-40 levels being available 
from slightly more subjects than neurogranin levels (see table 4). The YKL-40 MC group had 
a mean of 12 years left till symptom onset, while the neurogranin MC had a mean of 10 years 
left till symptom onset. No significant differences were found when comparing the absolute 
levels of YKL-40 and neurogranin between the MC and the NC. Even though the MC group 
was quite far from expected symptom onset in this study, they still had significantly lower 
levels of Ab42 and higher levels of t-tau and p-tau than the NC, indicating that they were past 
the initial stages of preclinical AD and had started to exhibit markers of amyloid pathology and 
neurodegeneration. That YKL-40 and neurogranin did not differentiate between the MC and 
the NC at this stage indicates that neither YKL-40 nor neurogranin can be considered to be 
early preclinical biomarkers of AD based on these results. The results do not contradict the 
results of a recent study which found no change in the levels of CSF YKL-40 in individuals 
with low CSF Ab42 and normal cognition, indicating that they were in the preclinical stage of 
AD. The same study found high YKL-40 levels in individuals with prodromal AD, i.e. with 
low CSF Ab42 and high t-tau and p-tau as well as subtle memory deficits (364). Contrary to 
this, neurogranin has been shown to be high in cognitively healthy individuals who later 
experienced a decline in cognition, as well as in healthy older subjects (with a mean age of 83 
years) with low Ab42 levels, indicative of preclinical AD (365). Why no such changes in 
neurogranin were observed in the study in paper IV is unclear, but the possibility exists that 
this is due to the small sample size. 
YKL-40 and neurogranin correlated positively with t-tau and p-tau in the MC, but no 
correlation was observed between Ab42 and either YKL-40 or neugranin in the MC group. 
Ab42 has been shown to decrease early, and non-linearly, in preclinical AD, and stay relatively 
stable and low throughout the course of the disease (36-38, 366), which can explain the lack of 
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correlation with Ab42. The positive correlation of YKL-40 and neurogranin with t-tau and p-
tau in the MC could be indicating that these two new biomarkers are reflecting aspects related 
to the neurodegeneration and tau hyperphosphorylation represented by t-tau and p-tau. 
Interestingly, YKL-40 and neurogranin correlated positively with t-tau, p-tau and Ab42 in the 
NC. The positive correlations with t-tau and p-tau could be explained by some of the NC 
finding themselves in the preclinical stage of AD, as the NC group is not exempt from 
developing SAD even though they do not carry a disease-causing mutation. One could thereby 
assume that YKL-40 and neurogranin are reflecting other pathophysiological changes related 
to preclinical AD in the NC group. However, the fact that YKL-40 and neurogranin correlated 
positively with Ab42 as well, contrary to what one would expect in preclinical AD, makes the 
matter more complicated and harder to interpret.  
YKL-40 correlated positively with years to symptom onset in both the MC and the NC, while 
no such correlation was found for neurogranin. Based on these results it is not possible to link 
either biomarker to early AD progression and this even suggests that YKL-40 might be an 
unspecific marker of the aging process. The longitudinal data on YKL-40 also showed an 
increase in YKL-40 levels as the age at symptom onset approached, with a steeper increase in 
the MC group. This suggests that YKL-40 might be a marker of a process related to normal 
aging which is exacerbated by a concomitant AD pathology. The same age dependent increase 
in CSF levels of YKL-40 has been observed previously in cognitively healthy middle aged 
individuals, with a sharper increase in carriers of the APOE e4 allele than in non-carriers (366). 
An increase in YKL-40 has been reported in AD dementia as well as in frontotemporal 
dementia and YKL-40 has also been associated with inflammatory processes in the CNS, such 
as multiple sclerosis (367, 368). Finally, YKL-40 expression has been shown to be markedly 
increased in astrocytes in the acute phases of cerebral infarction (368), further underpinning its 
possible role as an unspecific marker of CNS damage and aging. 
There were no signs of CSF neurogranin increasing over time in either the MC or the NC 
according to the longitudinal analysis. It is the rule, rather than the exception, that brains of 
elderly individuals exhibit multiple pathologies on autopsy, including loss of synapses (369). 
Here we have a young group of subjects who we suspect are mostly free of comorbidities which 
potentially could contribute to an increase in CSF neurogranin. From our results, it seems that 
preclinical AD alone is not enough to cause an increase in neurogranin, but if you add other 
comorbidities you might get a synergistic effect explaining the neurogranin increase seen in 
cognitively healthy elderly assumed to be in the preclinical stage of AD (365). 
In conclusion, the study presented in paper IV does not indicate that YKL-40 or neurogranin 
are early preclinical biomarkers of AD. However, there is a positive correlation between the 
levels of YKL-40 and increasing age, which is more pronounced in patients progressing from 
preclinical to symptomatic AD than in healthy controls. 
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5.4 PAPER III 
During the preparation of papers I and II the existence of a statistical outlier in the MC group 
came to our attention. This person, a carrier of the PSEN1 H163Y mutation, had normal levels 
of the CSF biomarkers Ab42, t-tau and p-tau, despite having passed the mean age of symptom 
onset in his family by 3 years. He was aware of his mutation status as he had opted for a 
presymptomatic genetic test and gave an informed written consent to the publication of a case 
report describing his clinical history and biomarker findings. In order to gain a clearer 
perspective on his case we included his brother, also a carrier of the PSEN1 H163Y mutation, 
in the case report. His brother (referred to as brother A) was one year older than the outlier 
(brother B) and both brothers were enrolled in the FAD study in 1995 (at the ages of 43 and 
44), undergoing regular follow-ups within the study for the next 22 years. We considered 
brother A to be a good control for brother B as the brothers were brought up in the same 
household and lived their lives in the same area. They also had similar levels of education (see 
paper III for a thorough description of the brothers’ backgrounds and clinical history). 
During the 22-year follow-up from 1995 to 2017 brother A developed dementia due to AD and 
finally passed away in a nursing home in 2017. Biomarkers in the CSF, on FDG-PET and PiB-
PET and on MRI all pointed to an underlying AD pathology and he experienced a typical 
cognitive decline on neuropsychological tests. Finally, the AD diagnosis was confirmed after 
a brain autopsy in 2017. He received a diagnosis of MCI at the age of 55, 4 years past the mean 
age of symptom onset in the family and a diagnosis of AD dementia a year later. He already 
had abnormal levels of CSF Ab42 11 years before the MCI diagnosis, at the age of 44. The 
same year he received the MCI diagnosis he had a decreased FDG uptake in the 
parahippocampus on PET and two years later this decrease was much more widespread. 
Increased PiB uptake was detected in all ROI´s except the thalamus 2 years after the MCI 
diagnosis (in 2008) and hippocampal atrophy on MRI 3 years after the MCI diagnosis. No 
presymptomatic PiB-PET examinations were available for brother A, but the widespread brain 
amyloidosis observed in 2008 leads to the suspicion that it had been present for some period of 
time before this examination. 
In contrast to brother A, brother B did not develop any definite signs or symptoms of AD during 
the 22-year follow-up. He had normal core AD biomarker levels in the CSF at the age of 54, 3 
years past the mean age at symptom onset in his family. He did not show signs of decreased 
FDG uptake on any of the FDG-PET examinations he underwent, the latest in 2009 (6 years 
past the mean age at symptom onset). Also, there was no detectable increase in PiB uptake on 
PET 9 years past the mean age at symptom onset (in 2012), using the grey matter of the pons 
as a reference. If the cerebellar grey matter was used as a reference however, there was a 
slightly elevated uptake of PiB in the posterior cingulate and the thalamus in 2009 and in both 
regions plus the anterior cingulate in 2012. This could indicate a possible incipient amyloid 
deposition. If that were the case one can assume the increased PiB uptake to be a very early 
sign of preclinical AD in brother B, as it is usually detected years or decades before the onset 
of the first cognitive symptoms. Brother B did not display any signs of cognitive decline on 
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repeated neuropsychological assessments, the last of which was made in 2017, 14 years past 
the expected onset of symptoms. If the PiB-PET results are a sign of the earliest stages of 
preclinical AD one would not expect brother B to develop symptoms for some years to come, 
probably not before he reaches the domain of late onset AD. 
The case of brother B is very interesting as no cases of reduced penetrance of FAD mutations 
have been described previously in the literature with such extensive prospective longitudinal 
follow-up and repeated biomarker measurements. Descriptions of wide ranges of ages at 
symptom onset in FAD families, as well as isolated cases of suspected reduced penetrance in 
particular subjects, have been reported  (100-103), but none with the support of longitudinal 
biomarker or neuropsychological data.  The findings in paper III have implications for genetic 
counseling as well as raise question about the possible mechanisms underlying the reduced 
penetrance in brother B.  
5.5 TEMPORAL TRAJECTORIES OF BIOMARKER CHANGES 
In the studies included in this thesis one of the main goals was to map the temporal trajectories 
of preclinical biomarker changes in our population of Swedish FAD mutation carriers. Figure 
9 summarizes the results obtained when correlating different biomarkers with years to 
symptom onset in this population. Some of these results are trends (CSF Ab42, t-tau, p-tau and 
the Ab42/p-tau ratio) while the others are statistically significant correlations. We feel that the 
trends belong in the figure as they are based on results from relatively few individuals, leading 
to a lack of statistical power which probably explains why the trends did not reach significance. 
In the figure, we have also incorporated published results from the FAD study which are not 
included in the papers comprising this thesis, as they involve the same subjects and are based 
on some of the same data. According to the summarized biomarker results it is CSF Ab42 that 
becomes abnormal first in preclinical AD, around 20 years before the expected symptom onset. 
This is followed by increased uptake of PiB on PET (around 17 years before symptom onset) 
(264), a decrease in the CSF Ab42/p-tau ratio (15 years before symptom onset), a decline in 
episodic memory, executive function and visuospatial function as measured on 
neuropsychological test (10 years from symptom onset) (370), decreased FDG uptake on PET 
(7 years before symptom onset) (264) and finally an increase in CSF t-tau and p-tau (around 5 
years before symptom onset). These results are in partial agreement with the hypothetical 
model of biomarker changes proposed by Jack et al. (17, 34). According to the hypothetical 
model it is CSF Ab42 and amyloid PET that become abnormal first, just as we observed in our 
studies. The order of the subsequent changes is somewhat different, with Jack et al. proposing 
that CSF tau changes next, followed by structural MRI and FDG-PET and finally by the 
emergence of cognitive impairment. Interestingly, we found that CSF t-tau and p-tau started to 
change around the same time as changes were observed on FDG-PET, suggesting that tau 
hyperphosphorylation and neurodegeneration have a close temporal relationship. Also, we 
found signs of cognitive decline on longitudinal neuropsychological tests quite early in the 
course of the disease. These signs of cognitive decline are subtle, reflected in a decline from 
baseline cognitive function on repeated tests, and usually not noticed by the patient until later. 
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This makes these changes of different character than the cognitive decline in the model by Jack 
et al. and therefore one cannot argue that these two biomarker models are in disagreement in 
this respect. The model by Jack et al. does not incorporate a marker such as YKL-40, which is 
believed to represent glial activation. In paper IV we observed changes in YKL-40 in the 
preclinical stage of AD, with YKL-40 increasing as the onset of symptoms approaches, more 
so in the MC than the NC. The data did not allow for an estimation of when the YKL-40 levels 
of the MC start to deviate from those of the NC. In a study involving the same population of 
Swedish FAD mutation carriers the MC showed high retention of DED on PET, signaling 
astrocytosis, very early in the preclinical stage, which then declined around the same time as 
an increase in PiB retention was first detected (264). This implies that inflammation might in 
fact precede the accumulation of amyloid. Finally, our studies did not reveal a correlation 
between structural changes on MRI and years to symptom onset. This suggests that structural 
MRI changes are downstream of the other biomarker changes presented in figure 9, or that the 
sample size was not large enough to detect these changes earlier on. 
 
 
Figure 9. Hypothetical temporal trajectories of biomarker changes in the preclinical stage of AD, based 
on the Swedish FAD study. All of the trajectories included in the figure are derived from longitudinal 
data, except for the trajectories of CSF Ab42, t-tau, p-tau and the Ab42/p-tau ratio, which are derived 
from cross-sectional data. The shape of the curves presented in the figure is strictly hypothetical, with 
the main purpose of the curves being to provide a visual summarization of the biomarker changes. Each 
curve symbolizes a change in a given biomarker starting at a given point in time, which may involve an 
increase or a decrease of the biomarker, even though all of the curves are positive in the figure for the 
sake of clarity. 
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6 LIMITATIONS 
Many of the limitations of the FAD study have already been discussed to some extent in the 
previous chapters of this thesis. One of the most important limitation is the relatively few 
participants in the study. This affects the statistical power of the study and increases the risk of 
significant differences between MC and NC going undetected. The small sample size does in 
some cases result in us having to use non-parametric statistical tests which are less likely to 
reveal significant differences. Also, even though correction for multiple comparisons was often 
necessary in our material, it causes the same problem by decreasing the statistical power. The 
small number of participants is a result of the rarity of FAD mutations in the general population. 
The Genetics unit at the Memory Clinic of the Karolinska University Hospital in Huddinge is 
a tertiary referral center for all Swedish cases of dementia with suspected autosomal dominant 
heritability. Therefore, one would not expect to find a significant amount of new FAD cases in 
Sweden and would have to collaborate with other countries in order to increase the number of 
participants. Finally, despite this sparsity of subjects, the Swedish FAD study still involves 
more participants than many of the other studies on FAD in the literature.  
Another limitation is the cross-sectional design of the studies in papers I and II. Cross-sectional 
data cannot reliably account for temporal changes in biomarkers, however it can give us a 
valuable indication of how these changes truly evolve over time. There were also some 
limitations to the longitudinal data presented in paper IV. The participants were of different 
ages at baseline, the time from baseline to first or second follow-up was quite variable between 
participants and not all of the participants returned for a second follow-up. These variations 
cause some difficulties in the statistical analysis of the longitudinal data, deducting somewhat 
from the reliability of the results. The root of these problems is again the small number of 
subjects, the reluctance of many of them to provide repeated CSF samples (limiting us to a 
cross-sectional analysis) and the fact that some of the subjects who underwent a repeated LP 
where not inclined to do so until some years after the first one. 
A lot of our results are based on relationships between different biomarkers and years to 
expected symptom onset. This allows us to estimate the place of a particular biomarker in the 
pathological cascade of AD and to compare our results to the results of other groups studying 
preclinical FAD. This is slightly problematic however, as different research group use different 
methods to define years to symptom onset. Some groups, like us, use the mean age at symptom 
onset of all affected members of a particular subject´s family to estimate his or her time to 
expected symptom onset. Other groups have used the age of the onset of symptoms in the 
subject´s affected parent to estimate this time. How different groups define symptom onset is 
also variable, some rely on the first reported cognitive symptoms by the affected individual (or 
an informant) while others use other reference points, e.g. the clinical diagnosis of AD. This 
can cause a discrepancy in how age at onset in different families is reported and in the reported 
time-points at which specific biomarker changes are observed. 
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Finally, there is always a possibility that results from studies on FAD cannot be generalized to 
SAD, and one must always keep that in mind when drawing conclusions from FAD studies. 
Also, the way different FAD mutations result in the development of AD dementia varies 
depending on the mutation. Thus, the composition of carriers of different mutations in each 
study, could possibly affect the results depending on the pathological mechanisms related to 
the mutation(s) in question. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  63 
7 CONCLUSIONS 
An array of biomarker changes was observed in a group of Swedish FAD mutation carriers, 
starting years to decades before the expected onset of cognitive symptoms. These markers 
imply that cerebral amyloidosis, glial activation, tau-phosphorylation and neurodegeneration 
all sequentially appear in these subjects before the emergence of clinical symptoms. It also 
seems that repeated neuropsychological assessments can detect an early deviation from 
baseline cognition in mutation carriers before the onset of subjective cognitive decline. 
These findings underpin the results of other studies pointing to similar preclinical biomarker 
changes, even though the exact order of events remains to be further elucidated. The results 
presented here are acquired from a relatively few participants, but are still highly significant in 
many cases, underlining the robustness of these biomarker changes. The chain of events in the 
preclinical stage of AD is of great interest as the root cause of AD is still under debate and 
biomarkers reflecting different pathological processes can shed light on cause and effect at this 
early stage of the disease. This in turn can be of guidance in the development of disease 
modifying treatments. In our results, biomarkers signaling cerebral amyloidosis were the 
earliest biomarkers to change in the MC, implying that amyloidosis is the event that sets the 
pathological cascade of AD in motion. However, the possibility remains that the biomarkers 
chosen in our studies fail to detect even earlier events related to other mechanisms. 
Our findings also put emphasis on the fact that different FAD mutations affect APP processing 
differently in vivo, but to date most of the information we have on such effects comes from in 
vitro studies. This renders support to our previous knowledge from in vitro studies, as well as 
underlines the fact that all FAD mutations cannot be assumed to behave in exactly the same 
way. The statistical outlier presented in paper III is another side of the same coin, showing no 
signs of underlying AD pathological changes, despite being many years past the expected 
symptom onset. This urges us to be cautious when providing genetic counseling and also in 
designing clinical trials involving preclinical FAD mutation carriers, as one cannot assume 
complete penetrance of FAD mutations in all mutation carriers.  
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8 FUTURE CONSIDERATIONS 
An attractive next step in studying biomarker changes in preclinical AD would be to embark 
on a larger multi-center longitudinal study. It would be of high interest to include greater 
numbers of symptom free FAD mutation carriers as well as carriers of risk alleles such as APOE 
e4. With sufficient resources, it would also be preferential to include a cohort of cognitively 
healthy older individuals. The subjects would then be followed-up at previously defined 
intervals with repeated collection of CSF and blood and with neuroimaging and 
neuropsychological assessments. Through such prospective collection of data from a large 
number of individuals, where a substantial part of the study group is expected to develop 
clinical AD during follow-up, one would be able to map the temporal trajectories of preclinical 
biomarker changes with precision, thereby gaining valuable knowledge on the true course of 
events during the development of AD. This proposed longitudinal biomarker study would 
benefit greatly from incorporating neuropathological examinations in order to validate the 
biomarker changes observed in vivo. The only way to ascertain that in vivo biomarker changes 
are reflecting pathological changes in the brain in the way we assume is through autopsy. A 
few studies with a similar study design as described here are already underway, i.e. the 
Dominantly Inherited Alzheimer Network (DIAN), a multi-center study on individuals 
carrying FAD mutations (38). 
Another interesting future direction would be to collect and characterize more cases of 
suspected reduced penetrance of FAD mutations found in other FAD studies around the globe. 
With a larger number of reduced penetrance cases it would be possible to pursue the underlying 
factor (or factors) causing these individuals to be spared from developing early-onset AD.  
Finally, asymptomatic FAD mutation carriers are optimal candidates for clinical trials on 
potential disease modifying treatments in AD, as such treatments are believed to be most 
effective during the preclinical phase of the disease. Ongoing clinical trials in this population 
include the DIAN trials unit (DIAN-TU) (371) and the Alzheimer’s preventive initiative (API) 
(372, 373). However, it has to be kept in mind that this involves several pitfalls, e.g. that study 
participants unaware of their mutation status could become aware through the development of 
side-effects, which presumably only affect mutation carriers as non-carriers would not receive 
active treatment. Also, the safety of such experimental treatments would have to be well 
established beforehand, as such studies would involve young, asymptomatic individuals, not 
patients, making the development of severe adverse events all the more devastating. 
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